{"id":"pacritinib","rwe":[{"pmid":"41851369","year":"2026","title":"Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.","finding":"","journal":"Bone marrow transplantation","studyType":"Clinical Study"},{"pmid":"41827733","year":"2026","title":"JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions.","finding":"","journal":"Cancers","studyType":"Clinical Study"},{"pmid":"41812252","year":"2026","title":"Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?","finding":"","journal":"Expert opinion on investigational drugs","studyType":"Clinical Study"},{"pmid":"41753113","year":"2026","title":"PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41504170","year":"2026","title":"Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.","finding":"","journal":"American journal of hematology","studyType":"Clinical Study"}],"_fda":{"id":"48c817fd-c902-46bb-b81c-10215d72a0a9","set_id":"4b5ab444-0e1a-4984-99db-76ad11a298ee","openfda":{"nui":["N0000175605","N0000020001","N0000190857","N0000182138","N0000182141","N0000185503","N0000190113","N0000191265"],"unii":["G22N65IL3O"],"route":["ORAL"],"rxcui":["2595248","2595254"],"spl_id":["48c817fd-c902-46bb-b81c-10215d72a0a9"],"brand_name":["Vonjo"],"spl_set_id":["4b5ab444-0e1a-4984-99db-76ad11a298ee"],"package_ndc":["72482-100-12"],"product_ndc":["72482-100"],"generic_name":["PACRITINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PACRITINIB"],"pharm_class_epc":["Kinase Inhibitor [EPC]"],"pharm_class_moa":["Tyrosine Kinase Inhibitors [MoA]","Janus Kinase Inhibitors [MoA]","Cytochrome P450 1A2 Inhibitors [MoA]","Cytochrome P450 3A4 Inhibitors [MoA]","P-Glycoprotein Inhibitors [MoA]","Breast Cancer Resistance Protein Inhibitors [MoA]","Organic Cation Transporter 1 Inhibitors [MoA]"],"manufacturer_name":["Sobi, Inc."],"application_number":["NDA208712"],"is_original_packager":[true]},"version":"9","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on VONJO use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, administration of pacritinib to pregnant mice or rabbits at exposures that were considerably lower than those observed at the recommended human dose were associated with maternal toxicity and embryonic and fetal loss (see Data ) . Advise pregnant women of the potential risk to a fetus. Consider the benefits and risks of VONJO for the mother and possible risks to the fetus when prescribing VONJO to a pregnant woman. The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Pacritinib was administered orally to pregnant mice at doses of 30, 100, or 250 mg/kg/day from gestation day 6 to gestation day 15. Pacritinib was also administered orally to pregnant rabbits at doses of 15, 30, or 60 mg/kg/day from gestation day 7 until gestation day 20. In both species, pacritinib was associated with maternal toxicity, which resulted in post-implantation loss in mice, abortions in rabbits, and reduced fetal body weights in mice and rabbits at exposures 0.1 times (mice) and 0.3 times (rabbits) the exposure at the recommended human dose (AUC-based). In mice, the high dose was associated with an increased incidence of an external malformation (cleft palate) in the presence of maternal toxicity. In a pre- and post-natal development study in mice, pregnant animals were dosed with pacritinib from implantation through lactation at 30, 100, or 250 mg/kg/day. Maternal toxicity was noted at 250 mg/kg and associated with increased gestation length and dystocia, lowered mean birth weights and neonatal survival, and transiently delayed startle response, learning, and memory development at weaning."],"overdosage":["10 OVERDOSAGE Overdosage may lead to gastrointestinal toxicities, myelosuppression, blurred vision, dizziness, worsening performance status, and sepsis. There is no known antidote for overdose with VONJO. Hemodialysis is not expected to enhance the elimination of VONJO."],"description":["11 DESCRIPTION VONJO contains pacritinib citrate, a kinase inhibitor with the chemical name (2E,16E)-11-[2-(pyrrolidin-1-yl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2,4,6,8,10,12(26),16,21,23-decaene citrate and a molecular weight of 664.7 as citrate salt and 472.59 as a free base. The molecular formula is C 28 H 32 N 4 O 3 •C 6 H 8 O 7 and the structural formula is: VONJO capsule is for oral administration. Each capsule contains 100 mg of pacritinib equivalent to 140.65 mg of pacritinib citrate and the inactive ingredients are microcrystalline cellulose NF, polyethylene glycol 8000 (PEG 8000) NF, and magnesium stearate NF. The gelatin capsule is bovine derived. The capsule shell contains gelatin, titanium dioxide, black iron oxide, erythrosine, red iron oxide, and printing ink containing shellac, propylene glycol, titanium dioxide, sodium hydroxide, and povidone. image description"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied VONJO is supplied in the following strength and package configuration: Strength NDC Number Description Capsules per Bottle 100 mg 72482-100-12 Hard, oblong, opaque, gelatin capsule with scarlet cap and gray body, printed with “Pacritinib 100 mg” on the cap and “C78837” on the body 120 16.2 Storage Store at room temperature, below 30°C (86°F). Keep the bottle tightly closed and protect from light. Store in original package. Dispense in original package or in a light-resistant container."],"geriatric_use":["8.5 Geriatric Use Clinical studies of VONJO did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20260325","clinical_studies":["14 CLINICAL STUDIES PERSIST-2 The efficacy of VONJO in the treatment of patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF was established in the PERSIST-2 trial. PERSIST-2 enrolled patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF with splenomegaly and a platelet count ≤100 × 10 9 /L. Both JAK2 naïve patients and patients with prior JAK2 inhibitor therapy were included. Patients were randomized 1:1:1 to receive VONJO 400 mg once daily, VONJO 200 mg twice daily, or best available therapy (BAT). BAT agents could be used alone, in combinations, sequentially, and intermittently, as clinically indicated by standards of care. BAT included any physician-selected treatment for MF and may have included ruxolitinib, hydroxyurea, glucocorticoids, erythropoietic agents, immunomodulatory agents, mercaptopurine, danazol, interferons, cytarabine, melphalan. BAT also included no treatment (“watch and wait”) or symptom-directed treatment without MF-specific treatment. In this trial, 311 patients were randomized to receive VONJO 400 mg once daily (n=104), VONJO 200 mg twice daily (n=107), or BAT (n=100). The VONJO dose of 400 mg once daily was not established as safe and is not an approved dosage regimen. The demographic characteristics of the efficacy population were median age of 68 years (range 32 to 91), 55% male, 86% Caucasian, and 14% non-Caucasian. The VONJO and BAT treatment arms were well balanced with respect to age, gender, race, ethnicity, body mass index, and geographic region. Sixty-eight percent of patients had primary MF, 20% had post-polycythemia vera MF, and 12% had post-essential thrombocythemia MF. Forty-six percent and 51% of patients in the VONJO and BAT treatment arms, respectively, had received prior ruxolitinib therapy. The median baseline hemoglobin level was 9.5 g/dL and 23% of patients were red blood cell (RBC) transfusion dependent at study entry. The median baseline platelet count was 55 × 10 9 /L; 45% of patients had a platelet count <50 × 10 9 /L. Patients had a baseline median spleen length of 14 cm assessed by magnetic resonance imaging (MRI) or computerized axial tomography (CAT). Efficacy was established in patients who received VONJO 200 mg twice daily and had a platelet count <50 x 10 9 (N=31). The most common agents used in the BAT treatment arm in patients with baseline platelet counts <50 × 10 9 /L (N=32) were ruxolitinib (39%), watchful waiting (32%), and hydroxyurea (26%). Spleen Volume Reduction The efficacy of VONJO in the treatment of patients with primary or secondary MF was established based upon the proportion of patients in the efficacy population receiving VONJO 200 mg twice daily or BAT achieving ≥35% spleen volume reduction from baseline to Week 24 as measured by magnetic resonance imaging or computed tomography. Efficacy results for spleen volume reduction in patients with a platelet count <50 × 10 9 /L are presented in Table 11 Table 11 Percentage of Patients Achieving ≥35% Reduction in Spleen Volume From Baseline to Week 24 in the Phase 3 Study, PERSIST-2 (Efficacy Population) Patient Population VONJO 200mg Twice Daily N=31 Best Available Therapy N=32 Baseline Platelets <50 × 10 9 /L 9 (29.0%) 1 (3.1%) 95% Confidence Interval (CI) 14.2, 48.0 0.1, 16.2 Difference (VONJO-BAT) 95% CI 25.9 (4.3,44.5) A waterfall plot of the percentage of change in spleen volume from baseline to Week 24 is presented in Figure 1 for the PERSIST-2 patients with baseline platelet counts <50 × 10 9 /L. The median reduction in spleen volume for patients with a platelet count <50 × 10 9 /L was 27.3% for patients in the VONJO 200 mg twice daily group compared to 0.9% in the BAT group. Figure 1 Waterfall Plot of Median Percent Change From Baseline in Spleen Volume at Week 24 in Patients With <50 × 109/L Platelet Counts in PERSIST-2 a a Dropout rates in VONJO and BAT arms were 26% and 44%, respectively. image description"],"pharmacodynamics":["12.2 Pharmacodynamics Pacritinib inhibited the phosphorylation of signal transducer and activator of transcription 5 (STAT5) protein in a dose-dependent manner (ex vivo) in expanded erythroid progenitor cells derived from healthy subjects. Administration of single doses of 400 mg pacritinib resulted in modest inhibition of interleukin-6-induced STAT3 phosphorylation in whole blood derived from healthy subjects. Cardiac Electrophysiology In a 24-week study of 54 patients with MF treated with VONJO 200 mg twice daily, the maximum mean (90% confidence interval) change in QTcF from baseline was 11 (90% CI: 5-17) msec."],"pharmacokinetics":["12.3 Pharmacokinetics Pacritinib steady-state mean (CV%) C max is 8.4 mg/L (32.4%) and AUC 0-12 is 95.6 mg×h/L (33.1%) following administration of VONJO 200 mg twice daily in patients with MF. Pharmacokinetics of pacritinib increases in a less than dose-proportional manner. VONJO 200 mg twice daily accumulates 386% and reaches steady-state within a week. Absorption Pacritinib achieves C max within approximately 4 to 5 hours post-dose. Effect of Food There was no significant effect of food on the pharmacokinetics of pacritinib following oral administration of VONJO 200 mg with a high-fat meal. Distribution The median (range) apparent volume of distribution of pacritinib at steady state is 229 L (156 to 591 L) in patients with MF taking 200 mg twice daily. Plasma protein binding of pacritinib is approximately 98.8%. Metabolism Pacritinib is predominantly metabolized by the CYP3A4 isozyme. Pacritinib is the major circulating component and the pharmacologic activity is mainly attributed to the parent molecule. Two major metabolites, M1 and M2, in human whole plasma represent 9.6% and 10.5% of parent drug exposure, respectively. Elimination The mean apparent clearance at steady-state (CV%) of pacritinib is 2.09 L/h (33.1%), and mean effective half-life (CV%) is 27.7 hours (17.0%). Excretion Following a single oral administration of radiolabeled pacritinib 400 mg in healthy adult subjects, 87% of the radioactivity was recovered in feces, and 6% was recovered in urine. No unchanged drug was excreted in feces and 0.12% of unchanged drug was excreted in urine. Specific Populations No clinically significant differences in the pharmacokinetics of pacritinib were observed based on age, sex, body weight, or race. Patients With Renal Impairment Pacritinib C max and AUC were similar in subjects with eGFR 30 to 89 mL/min, as estimated by the MDRD study equation, compared to subjects with eGFR ≥90 mL/min. The C max and AUC increased approximately 30% in subjects with eGFR 15 to 29 mL/min and eGFR <15 mL/min on hemodialysis. Patients With Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of pacritinib was studied in subjects with normal or impaired hepatic function at 200 mg VONJO twice daily for 14 days. The geometric mean AUC of total pacritinib decreased in subjects with moderate [Child-Pugh B, n=8] or severe hepatic impairment [Child-Pugh C, n=6] compared to subjects with normal hepatic function (n=11) due to reduced plasma protein binding. The geometric mean AUC of unbound pacritinib, the pharmacologically relevant parameter, was similar in healthy subjects compared to subjects with moderate hepatic impairment and increased by 23% in subjects with severe hepatic impairment (see Table 6). Table 6 Steady-State Pharmacokinetic Changes in Pacritinib at 200 mg VONJO BID: Subjects with Moderate / Severe Hepatic Impairment vs. Normal Hepatic Function Hepatic impairment Ratio (90% CI) of pacritinib exposure 1 Unbound C max Unbound AUC 0-tau Moderate impairment (Child-Pugh B) 1.06 (0.72, 1.58) 1.05 (0.69, 1.60) Severe impairment (Child-Pugh C) 1.24 (0.93, 1.65) 1.23 (0.91, 1.66) Notes: AUC 0-tau = Area under the curve from zero to tau post-dose after 14 days twice daily dosing with VONJO 200 mg; CI = Confidence Interval; C max = Maximum plasma concentration. 1 Ratios for C max and AUC compare exposure of unbound pacritinib in subjects with hepatic impairment vs normal hepatic function following administration of VONJO 200 mg BID for 14 days. Drug Interactions Effects of Other Drugs on the Pharmacokinetics of VONJO The effect of co-administered drugs on the exposure of pacritinib is shown in Table 7 and Table 8. Table 7 Change in Pharmacokinetics of Pacritinib Following Administration of a Single 400 mg Dose VONJO in the Presence of Co-administered Drugs Co-administered Drug Regimen of Co-administered Drug Ratio (90% CI) of pacritinib exposure 1 C max AUC 0-t Clarithromycin (strong CYP3A4 inhibitor) 500 mg every 12 hours for 5 days 1.30 (1.22, 1.39) 1.80 (1.67, 1.94) Rifampin (strong CYP3A4 inducer) 600 mg once daily for 10 days 0.49 (0.43, 0.55) 0.13 (0.11, 0.15) Notes: AUC 0-t = Area under the curve from zero to the last quantifiable concentration; CI = Confidence interval; CYP = Cytochrome P450 1 Ratios for C max and AUC compare co-administration of the medication with VONJO vs. administration of single dose 400 mg VONJO alone Table 8 Change in Pharmacokinetics of 200 mg VONJO BID at Steady State in the Presence of Co-administered Drugs Co-administered Drug Regimen of Co-administered Drug Ratio (90% CI) of pacritinib exposure 1 C max AUC 0-tau Fluconazole (moderate CYP3A4 inhibitor) 200 mg once daily for 7 days 1.41 (1.35, 1.48) 1.45 (1.39, 1.52) Bosentan (moderate CYP3A4 inducer) 125 mg twice daily for 7 days 0.84 (0.76, 0.92) 0.79 (0.72, 0.87) Notes: AUC 0-tau = Area under the curve for a dosing interval; BID = Twice daily; CI = Confidence interval; C max = Maximum plasma concentration; CYP = Cytochrome P450. 1 Ratios for C max and AUC 0-tau compare co-administration of the medication with 200 mg VONJO BID vs. administration of 200 mg VONJO alone at steady state. Effects of VONJO on the Pharmacokinetics of Other Drugs The effect of pacritinib on the exposure of other co-administered drugs is shown in Table 9. Table 9 Change in Pharmacokinetics of Co-administered Drugs with 200 mg VONJO BID at Steady State Co-administered Drug Regimen of Co-administered Drug (single dose) Ratio (90% CI) of exposure of co-administered drug 1 C max AUC Caffeine (CYP1A2 substrate) 100 mg 0.99 (0.92, 1.07) 1.22 (1.12, 1.32) Midazolam (CYP3A4 substrate) 2 mg 0.40 (0.34, 0.46) 0.40 (0.35, 0.46) Omeprazole (CYP2C19 substrate) 20 mg 0.73 (0.46, 1.15) 0.49 (0.27, 0.89) Notes: AUC = Area under the curve from zero to the last quantifiable concentration displayed for caffeine and AUC from zero extrapolated to infinity displayed for midazolam and omeprazole; BID = Twice daily; CI = Confidence interval; C max = Maximum plasma concentration; CYP = Cytochrome P450. 1 Ratios for C max and AUC compare a single dose of co-administered drug with 200 mg VONJO BID at steady state vs. administration of a single dose of the co-administered drug alone. In Vitro Studies Cytochrome P450 (CYP) Enzymes: Pacritinib is a time-dependent inhibitor of CYP1A2 and CYP3A4, and a reversible inhibitor of CYP3A4 and CYP2C19 (Ki ≤10 µM). Pacritinib shows less direct inhibition towards CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (Ki >10 µM). Pacritinib is an inducer of CYP1A2 and CYP3A4. Transporter Systems Table 10 Change in Pharmacokinetics of Co-administered Drugs with 200 mg VONJO BID at Steady State Co-administered Drug Regimen of Co-administered Drug (single dose) Ratio (90% CI) of exposure of co-administered drug 1 C max AUC Metformin (OCT1 substrate) 500 mg 0.96 (0.87, 1.07) 1.05 (0.96, 1.15) Digoxin (P-gp substrate) 0.25 mg 1.29 (1.13, 1.47) 1.15 (1.05, 1.27) Rosuvastatin (BCRP substrate) 5 mg 2.04 (1.79, 2.31) 1.80 (1.63, 1.99) Notes: AUC = Area under the curve from zero to the last quantifiable concentration displayed for digoxin and rosuvastatin and AUC from zero extrapolated to infinity displayed for metformin; BID = Twice daily; CI = Confidence interval; C max = Maximum plasma concentration; CYP = Cytochrome P450 1 Ratios for C max and AUC compare a single dose of co-administered drug with 200 mg VONJO BID at steady state vs. administration of a single dose of the co-administered drug alone. In Vitro Studies Transporter Systems: Pacritinib is not a substrate of BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or P-gp. Pacritinib is an inhibitor of BCRP, OCT1, OCT2, and P-gp. Pacritinib is not an inhibitor of BSEP, MRP2, OAT1, or OAT3."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hemorrhage [see Warnings and Precautions ( 5.1 )] Diarrhea [see Warnings and Precautions ( 5.2 )] Thrombocytopenia [see Warnings and Precautions ( 5.3 )] Prolonged QT Interval [see Warnings and Precautions ( 5.4 )] Major Adverse Cardiac Events [see Warnings and Precautions ( 5.5 )] Thrombosis [see Warnings and Precautions ( 5.6 )] Secondary Malignancies [see Warnings and Precautions ( 5.7 )] Risk of Infection [see Warnings and Precautions ( 5.8 )] Symptom Exacerbation Following Interruption or Discontinuation of Treatment [see Warnings and Precautions ( 5.9 )] The most common (≥20% of patients) adverse reactions are diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Sobi, Inc. at (866) 773-5274 and www.VONJO.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. PERSIST-2 Trial The safety of VONJO was evaluated in the randomized, controlled PERSIST-2 trial [see Clinical Studies ( 14 )] . In PERSIST-2, key eligibility criteria included adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF with splenomegaly and a platelet count ≤100 × 10 9 /L. Prior Janus associated kinase (JAK) inhibitor therapy was permitted. Patients received VONJO at 200 mg twice daily (n=106), 400 mg once daily (n=104), or best available therapy (BAT) (n=98). Forty-seven (44%) of the 106 patients treated with VONJO 200 mg twice daily had a baseline platelet count of <50 × 10 9 /L. The 400 mg once daily dose could not be established to be safe, so further information on this arm is not provided. In PERSIST-2, among the 106 patients treated with VONJO 200 mg twice daily, the median baseline hemoglobin was 9.7 g/dL and the median drug exposure was 25 weeks. Fifty-four percent of patients were exposed for 6 months, and 18% were exposed for approximately 12 months. Accounting for dose reductions, the average daily dose (mean relative dose intensity) and median daily dose (median relative dose intensity) were 380 mg (95%) and 400 mg (100%), respectively, for patients receiving VONJO twice daily. The median age of patients who received VONJO 200 mg twice daily was 67 years (range: 39 to 85 years), 59% were male, 86% were White, 3% were Asian, 2% were Native Hawaiian or Other Pacific Islander, 0% were Black, 9% did not report race, and 87% had an Eastern Cooperative Oncology Group performance status of 0 to 1. Serious adverse reactions occurred in 47% of patients treated with VONJO 200 mg twice daily and in 31% of patients treated with BAT. The most frequent serious adverse reactions occurring in ≥3% patients receiving VONJO 200 mg twice daily were anemia (8%), thrombocytopenia (6%), pneumonia (6%), cardiac failure (4%), disease progression (3%), pyrexia (3%), and squamous cell carcinoma of skin (3%). Fatal adverse reactions occurred in 8% of patients receiving VONJO 200 mg twice daily and in 9% of patients treated with BAT. The fatal adverse reactions among patients treated with VONJO 200 mg twice daily included events of disease progression (3%), and multiorgan failure, cerebral hemorrhage, meningorrhagia, and acute myeloid leukemia in <1% of patients each, respectively. Permanent discontinuation due to an adverse reaction occurred in 15% of patients receiving VONJO 200 mg twice daily compared to 12% of patients treated with BAT. The most frequent reasons for permanent discontinuation in ≥2% of patients receiving VONJO 200 mg twice daily included anemia (3%) and thrombocytopenia (2%). Drug interruptions due to an adverse reaction occurred in 27% of patients who received VONJO 200 mg twice daily compared to 10% of patients treated with BAT. The most frequent reasons for drug interruption in ≥2% of patients receiving VONJO 200 mg twice daily were anemia (5%), thrombocytopenia (4%), diarrhea (3%), nausea (3%), cardiac failure (3%), neutropenia (2%), and pneumonia (2%). Dosage reductions due to an adverse reaction occurred in 12% of patients who received VONJO 200 mg twice daily compared to 7% of patients treated with BAT. Adverse reactions requiring dosage reduction in ≥2% of patients who received VONJO 200 mg twice daily included thrombocytopenia (2%), neutropenia (2%), conjunctival hemorrhage (2%), and epistaxis (2%). The most common adverse reactions in ≥20% of patients (N=106) were diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema. Table 5 summarizes the common adverse reactions in PERSIST-2 during randomized treatment. Table 5 Adverse Reactions Reported in ≥10% Patients Receiving VONJO 200 mg Twice Daily or Best Available Therapy During Randomized Treatment in PERSIST-2 a Grade by CTCAE Version 4.03 Adverse Reactions VONJO (200 mg Twice Daily) (N=106) Best Available Therapy (N=98) All Grades a % Grade ≥3 % All Grades a % Grade ≥3 % Diarrhea 48 4 15 0 Thrombocytopenia 34 32 23 18 Nausea 32 1 11 1 Anemia 24 22 15 14 Peripheral edema 20 1 15 0 Vomiting 19 0 5 1 Dizziness 15 1 5 0 Pyrexia 15 1 3 0 Epistaxis 12 5 13 1 Dyspnea 10 0 9 3 Pruritus 10 2 6 0 Upper respiratory tract infection 10 0 6 0 Cough 8 2 10 0 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of VONJO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Renal: Acute or subacute kidney injury (secondary to diarrhea) [see Warnings and Precautions (5.2)]"],"contraindications":["4 CONTRAINDICATIONS VONJO is contraindicated in patients concomitantly using strong CYP3A4 inhibitors or inducers as these medications can significantly alter exposure to pacritinib, which may increase the risk of adverse reactions or impair efficacy [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 , 5.4 ), Drug Interactions ( 7.1 ), and Clinical Pharmacology ( 12.3 )] . Concomitant use of strong CYP3A4 inhibitors or inducers ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Co-administration of VONJO with moderate CYP3A4 inhibitors can increase the exposure to pacritinib. Monitor for increased adverse reactions of VONJO when administered with moderate CYP3A4 inhibitors ( 7.1 ). VONJO is an inhibitor of P-gp, BCRP, and CYP1A2 and an inducer of CYP3A4 and CYP2C19. Monitor patients concomitantly receiving substrates of these transporters and enzymes, and adjust dose of the substrates as needed ( 7.2 ). VONJO may reduce the effectiveness of hormonal contraceptives ( 7.2 ) 7.1 Effect of Other Drugs on VONJO Strong and Moderate CYP3A4 Inhibitors Pacritinib is predominantly metabolized by CYP3A4. Concomitant use of VONJO with strong and moderate CYP3A4 inhibitors increases pacritinib exposure, which may increase the risk of exposure-related adverse reactions [see Clinical Pharmacology ( 12.3 )] Co-administration of VONJO with strong CYP3A4 inhibitors is contraindicated [see Contraindications ( 4 )]. Monitor patients concomitantly receiving moderate CYP3A4 inhibitors (e.g., fluconazole) for increased adverse reactions and consider VONJO dose modifications based on safety [see Dosage and Administration ( 2.5 )] . Concomitant use of VONJO with doses of fluconazole greater than 200 mg once daily has not been studied. Strong CYP3A4 Inducers Pacritinib is predominantly metabolized by CYP3A4. Concomitant use of VONJO with strong CYP3A4 inducers decreases pacritinib exposure, which may reduce efficacy of VONJO [see Clinical Pharmacology ( 12.3 )] . Co-administration of VONJO with strong CYP3A4 inducers is contraindicated [see Contraindications ( 4 )]. 7.2 Effect of VONJO on Other Drugs CYP1A2 Substrates Pacritinib is an inhibitor of CYP1A2. VONJO increases the plasma concentrations of CYP1A2 substrates [see Clinical Pharmacology ( 12.3 )] ,which may increase the risk of adverse reactions from the CYP1A2 substrate. Monitor for CYP1A2 substrate related adverse reactions more frequently, unless otherwise recommended in the substrate Prescribing Information, when VONJO is used concomitantly with CYP1A2 substrates where minimal substrate concentration changes may lead to serious adverse reactions. CYP2C19 Substrates Pacritinib is an inducer of CYP2C19. VONJO decreases the plasma concentrations of CYP2C19 substrates [see Clinical Pharmacology ( 12.3 )] , which may decrease the efficacy from the CYP2C19 substrate. Monitor the efficacy of CYP2C19 substrate more frequently, unless otherwise recommended in the substrate Prescribing Information, when VONJO is used concomitantly with CYP2C19 substrates where minimal substrate concentration changes may lead to diminished efficacy. Dose adjustment of CYP2C19 substrates may be needed. CYP3A4 Substrates Pacritinib is an inducer of CYP3A4. VONJO decreases the plasma concentrations of CYP3A4 substrates [see Clinical Pharmacology ( 12.3 )] , which may decrease the efficacy from the CYP3A4 substrate. Monitor the efficacy of CYP3A4 substrate more frequently, unless otherwise recommended in the substrate Prescribing Information, when VONJO is used concomitantly with CYP3A4 substrates where minimal substrate concentration changes may lead to diminished efficacy. Dose adjustment of CYP3A4 substrates may be needed. Hormonal Contraceptives Avoid concomitant use of VONJO with hormonal contraceptives except for intrauterine systems containing levonorgestrel. The effectiveness of hormonal contraceptives, except for intrauterine systems containing levonorgestrel, may be reduced when used with VONJO. If contraception is needed or desired, an alternate contraceptive that is not affected by CYP3A4 inducers (e.g., an intrauterine system) or additional nonhormonal contraceptive (e.g., condoms) should be used when treated concomitantly with VONJO, and for 30 days after last dose of VONJO. P-gp Substrates Pacritinib is an inhibitor of P-gp. VONJO increases the plasma concentrations of P-gp substrates [see Clinical Pharmacology ( 12.3 )] , which may increase the risk of adverse reactions from the P-gp substrate. Monitor for P-gp substrate related adverse reactions more frequently, unless otherwise recommended in the substrate Prescribing Information, when VONJO is used concomitantly with P-gp substrates where minimal substrate concentration changes may lead to serious adverse reactions. Digoxin: Measure serum digoxin concentrations before initiating concomitant use with VONJO and continue monitoring serum digoxin concentrations as recommended in the Prescribing Information for digoxin [see Clinical Pharmacology ( 12.3 )] . BCRP substrates Pacritinib is an inhibitor of BCRP. VONJO increases the plasma concentrations of BCRP substrates [see Clinical Pharmacology ( 12.3 )] , which may increase the risk of adverse reactions from the BCRP substrate. When used concomitantly with VONJO, monitor for BCRP substrate related adverse reactions more frequently and consider dose reduction of the BCRP substrate according to its Prescribing Information. Rosuvastatin: The dose of rosuvastatin should not exceed 20 mg once daily when concomitantly used with VONJO [see Clinical Pharmacology ( 12.3 )] ."],"how_supplied_table":["
StrengthNDC NumberDescriptionCapsules per Bottle
100 mg72482-100-12Hard, oblong, opaque, gelatin capsule with scarlet cap and gray body, printed with “Pacritinib 100 mg” on the cap and “C78837” on the body120
"],"mechanism_of_action":["12.1 Mechanism of Action Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3), and interleukin 1 receptor associated kinase-1 (IRAK1) which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Pacritinib is also an inhibitor of activin A receptor, type 1/activin receptor like-kinase 2 (ACVR1/ALK2). MF is often associated with dysregulated JAK2 signaling. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib has higher inhibitory activity for JAK2 compared to JAK3 and tyrosine kinase 2 (TYK2). Pacritinib exhibits inhibitory activity against additional cellular kinases, such as colony stimulating factor 1 receptor (CSF1R), of which the clinical relevance in myelofibrosis is unknown."],"recent_major_changes":["Warnings and Precautions ( 5.9 ) 11/2024 Warnings and Precautions ( 5.2 ) 08/2025 Dosage and Administration ( 2.6 ) 10/2025 Warnings and Precautions ( 5.9 ) 03/2026"],"storage_and_handling":["16.2 Storage Store at room temperature, below 30°C (86°F). Keep the bottle tightly closed and protect from light. Store in original package. Dispense in original package or in a light-resistant container."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3), and interleukin 1 receptor associated kinase-1 (IRAK1) which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Pacritinib is also an inhibitor of activin A receptor, type 1/activin receptor like-kinase 2 (ACVR1/ALK2). MF is often associated with dysregulated JAK2 signaling. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib has higher inhibitory activity for JAK2 compared to JAK3 and tyrosine kinase 2 (TYK2). Pacritinib exhibits inhibitory activity against additional cellular kinases, such as colony stimulating factor 1 receptor (CSF1R), of which the clinical relevance in myelofibrosis is unknown. 12.2 Pharmacodynamics Pacritinib inhibited the phosphorylation of signal transducer and activator of transcription 5 (STAT5) protein in a dose-dependent manner (ex vivo) in expanded erythroid progenitor cells derived from healthy subjects. Administration of single doses of 400 mg pacritinib resulted in modest inhibition of interleukin-6-induced STAT3 phosphorylation in whole blood derived from healthy subjects. Cardiac Electrophysiology In a 24-week study of 54 patients with MF treated with VONJO 200 mg twice daily, the maximum mean (90% confidence interval) change in QTcF from baseline was 11 (90% CI: 5-17) msec. 12.3 Pharmacokinetics Pacritinib steady-state mean (CV%) C max is 8.4 mg/L (32.4%) and AUC 0-12 is 95.6 mg×h/L (33.1%) following administration of VONJO 200 mg twice daily in patients with MF. Pharmacokinetics of pacritinib increases in a less than dose-proportional manner. VONJO 200 mg twice daily accumulates 386% and reaches steady-state within a week. Absorption Pacritinib achieves C max within approximately 4 to 5 hours post-dose. Effect of Food There was no significant effect of food on the pharmacokinetics of pacritinib following oral administration of VONJO 200 mg with a high-fat meal. Distribution The median (range) apparent volume of distribution of pacritinib at steady state is 229 L (156 to 591 L) in patients with MF taking 200 mg twice daily. Plasma protein binding of pacritinib is approximately 98.8%. Metabolism Pacritinib is predominantly metabolized by the CYP3A4 isozyme. Pacritinib is the major circulating component and the pharmacologic activity is mainly attributed to the parent molecule. Two major metabolites, M1 and M2, in human whole plasma represent 9.6% and 10.5% of parent drug exposure, respectively. Elimination The mean apparent clearance at steady-state (CV%) of pacritinib is 2.09 L/h (33.1%), and mean effective half-life (CV%) is 27.7 hours (17.0%). Excretion Following a single oral administration of radiolabeled pacritinib 400 mg in healthy adult subjects, 87% of the radioactivity was recovered in feces, and 6% was recovered in urine. No unchanged drug was excreted in feces and 0.12% of unchanged drug was excreted in urine. Specific Populations No clinically significant differences in the pharmacokinetics of pacritinib were observed based on age, sex, body weight, or race. Patients With Renal Impairment Pacritinib C max and AUC were similar in subjects with eGFR 30 to 89 mL/min, as estimated by the MDRD study equation, compared to subjects with eGFR ≥90 mL/min. The C max and AUC increased approximately 30% in subjects with eGFR 15 to 29 mL/min and eGFR <15 mL/min on hemodialysis. Patients With Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of pacritinib was studied in subjects with normal or impaired hepatic function at 200 mg VONJO twice daily for 14 days. The geometric mean AUC of total pacritinib decreased in subjects with moderate [Child-Pugh B, n=8] or severe hepatic impairment [Child-Pugh C, n=6] compared to subjects with normal hepatic function (n=11) due to reduced plasma protein binding. The geometric mean AUC of unbound pacritinib, the pharmacologically relevant parameter, was similar in healthy subjects compared to subjects with moderate hepatic impairment and increased by 23% in subjects with severe hepatic impairment (see Table 6). Table 6 Steady-State Pharmacokinetic Changes in Pacritinib at 200 mg VONJO BID: Subjects with Moderate / Severe Hepatic Impairment vs. Normal Hepatic Function Hepatic impairment Ratio (90% CI) of pacritinib exposure 1 Unbound C max Unbound AUC 0-tau Moderate impairment (Child-Pugh B) 1.06 (0.72, 1.58) 1.05 (0.69, 1.60) Severe impairment (Child-Pugh C) 1.24 (0.93, 1.65) 1.23 (0.91, 1.66) Notes: AUC 0-tau = Area under the curve from zero to tau post-dose after 14 days twice daily dosing with VONJO 200 mg; CI = Confidence Interval; C max = Maximum plasma concentration. 1 Ratios for C max and AUC compare exposure of unbound pacritinib in subjects with hepatic impairment vs normal hepatic function following administration of VONJO 200 mg BID for 14 days. Drug Interactions Effects of Other Drugs on the Pharmacokinetics of VONJO The effect of co-administered drugs on the exposure of pacritinib is shown in Table 7 and Table 8. Table 7 Change in Pharmacokinetics of Pacritinib Following Administration of a Single 400 mg Dose VONJO in the Presence of Co-administered Drugs Co-administered Drug Regimen of Co-administered Drug Ratio (90% CI) of pacritinib exposure 1 C max AUC 0-t Clarithromycin (strong CYP3A4 inhibitor) 500 mg every 12 hours for 5 days 1.30 (1.22, 1.39) 1.80 (1.67, 1.94) Rifampin (strong CYP3A4 inducer) 600 mg once daily for 10 days 0.49 (0.43, 0.55) 0.13 (0.11, 0.15) Notes: AUC 0-t = Area under the curve from zero to the last quantifiable concentration; CI = Confidence interval; CYP = Cytochrome P450 1 Ratios for C max and AUC compare co-administration of the medication with VONJO vs. administration of single dose 400 mg VONJO alone Table 8 Change in Pharmacokinetics of 200 mg VONJO BID at Steady State in the Presence of Co-administered Drugs Co-administered Drug Regimen of Co-administered Drug Ratio (90% CI) of pacritinib exposure 1 C max AUC 0-tau Fluconazole (moderate CYP3A4 inhibitor) 200 mg once daily for 7 days 1.41 (1.35, 1.48) 1.45 (1.39, 1.52) Bosentan (moderate CYP3A4 inducer) 125 mg twice daily for 7 days 0.84 (0.76, 0.92) 0.79 (0.72, 0.87) Notes: AUC 0-tau = Area under the curve for a dosing interval; BID = Twice daily; CI = Confidence interval; C max = Maximum plasma concentration; CYP = Cytochrome P450. 1 Ratios for C max and AUC 0-tau compare co-administration of the medication with 200 mg VONJO BID vs. administration of 200 mg VONJO alone at steady state. Effects of VONJO on the Pharmacokinetics of Other Drugs The effect of pacritinib on the exposure of other co-administered drugs is shown in Table 9. Table 9 Change in Pharmacokinetics of Co-administered Drugs with 200 mg VONJO BID at Steady State Co-administered Drug Regimen of Co-administered Drug (single dose) Ratio (90% CI) of exposure of co-administered drug 1 C max AUC Caffeine (CYP1A2 substrate) 100 mg 0.99 (0.92, 1.07) 1.22 (1.12, 1.32) Midazolam (CYP3A4 substrate) 2 mg 0.40 (0.34, 0.46) 0.40 (0.35, 0.46) Omeprazole (CYP2C19 substrate) 20 mg 0.73 (0.46, 1.15) 0.49 (0.27, 0.89) Notes: AUC = Area under the curve from zero to the last quantifiable concentration displayed for caffeine and AUC from zero extrapolated to infinity displayed for midazolam and omeprazole; BID = Twice daily; CI = Confidence interval; C max = Maximum plasma concentration; CYP = Cytochrome P450. 1 Ratios for C max and AUC compare a single dose of co-administered drug with 200 mg VONJO BID at steady state vs. administration of a single dose of the co-administered drug alone. In Vitro Studies Cytochrome P450 (CYP) Enzymes: Pacritinib is a time-dependent inhibitor of CYP1A2 and CYP3A4, and a reversible inhibitor of CYP3A4 and CYP2C19 (Ki ≤10 µM). Pacritinib shows less direct inhibition towards CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (Ki >10 µM). Pacritinib is an inducer of CYP1A2 and CYP3A4. Transporter Systems Table 10 Change in Pharmacokinetics of Co-administered Drugs with 200 mg VONJO BID at Steady State Co-administered Drug Regimen of Co-administered Drug (single dose) Ratio (90% CI) of exposure of co-administered drug 1 C max AUC Metformin (OCT1 substrate) 500 mg 0.96 (0.87, 1.07) 1.05 (0.96, 1.15) Digoxin (P-gp substrate) 0.25 mg 1.29 (1.13, 1.47) 1.15 (1.05, 1.27) Rosuvastatin (BCRP substrate) 5 mg 2.04 (1.79, 2.31) 1.80 (1.63, 1.99) Notes: AUC = Area under the curve from zero to the last quantifiable concentration displayed for digoxin and rosuvastatin and AUC from zero extrapolated to infinity displayed for metformin; BID = Twice daily; CI = Confidence interval; C max = Maximum plasma concentration; CYP = Cytochrome P450 1 Ratios for C max and AUC compare a single dose of co-administered drug with 200 mg VONJO BID at steady state vs. administration of a single dose of the co-administered drug alone. In Vitro Studies Transporter Systems: Pacritinib is not a substrate of BCRP, MRP2, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or P-gp. Pacritinib is an inhibitor of BCRP, OCT1, OCT2, and P-gp. Pacritinib is not an inhibitor of BSEP, MRP2, OAT1, or OAT3."],"indications_and_usage":["1 INDICATIONS AND USAGE VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). VONJO is a kinase inhibitor indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10 9 /L ( 1 ). This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s)."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hemorrhage: Avoid use in patients with active bleeding and hold VONJO prior to any planned surgical procedures. May require dose interruption, dose reduction or permanent discontinuation depending on severity ( 5.1 ). Diarrhea: Manage significant diarrhea with anti-diarrheals, dose reduction, or dose interruption ( 5.2 ). Thrombocytopenia: Manage by dose reduction or interruption ( 5.3 ). Prolonged QT Interval: Avoid use in patients with baseline QTc >480 msec. Interrupt and reduce VONJO dosage in patients who have a QTcF >500 msec. Correct hypokalemia prior to and during VONJO administration ( 5.4 ). Major Adverse Cardiac Events (MACE): Risk may be increased in current/past smokers and patients with other cardiovascular risk factors. Monitor for signs, evaluate and treat promptly ( 5.5 ). Thrombosis: Including deep venous thrombosis, pulmonary embolism, and arterial thrombosis may occur. Monitor for signs, evaluate and treat promptly ( 5.6 ). Secondary Malignancies: Lymphoma and other malignancies may occur. Past/current smokers may be at increased risk ( 5.7 ). Risk of Infection: Delay starting VONJO until active serious infections have resolved. Observe for signs and symptoms of infection and manage promptly ( 5.8 ). Symptom Exacerbation Following Interruption or Discontinuation: Manage with supportive care and consider resuming treatment with VONJO ( 5.9 ). 5.1 Hemorrhage Serious (11%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <100 x 10 9 /L. Serious (13%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <50 x 10 9 /L. Grade ≥3 bleeding events (defined as requiring transfusion or invasive intervention) occurred in 15% of patients treated with VONJO compared to 7% of patients treated on the control arm. Due to hemorrhage, VONJO dose-reductions, dose interruptions, or permanent discontinuations occurred in 3%, 3%, and 5% of patients, respectively. Avoid use of VONJO in patients with active bleeding and hold VONJO 7 days prior to any planned surgical or invasive procedures. Assess platelet counts periodically, as clinically indicated [see Warnings and Precautions ( 5.3 )] . Manage hemorrhage using treatment interruption and medical intervention [see Dosage and Administration ( 2.5 )] . 5.2 Diarrhea VONJO caused diarrhea in approximately 48% of patients compared to 15% of patients treated on the control arm in a clinical trial. The median time to resolution in VONJO-treated patients was 2 weeks. The incidence of reported diarrhea decreased over time with 41% of patients reporting diarrhea in the first 8 weeks of treatment, 15% in Weeks 8 through 16, and 8% in Weeks 16 through 24. Diarrhea resulted in treatment interruption in 3% of VONJO-treated patients. Serious diarrhea adverse reactions occurred in 2% of patients treated with VONJO compared to no such adverse reactions in patients in the control arm. In postmarketing reports, severe diarrhea leading to acute kidney injury and treatment discontinuation has been reported with VONJO. Control pre-existing diarrhea before starting VONJO treatment. Manage diarrhea with antidiarrheal medications, fluid replacement, and dose-modification. Upon initiation of therapy, prescribe an anti-diarrheal medication (e.g., loperamide), and instruct patients to treat diarrhea promptly at the first onset of symptoms (change in frequency or consistency of bowel movements) after starting VONJO. Interrupt or reduce VONJO dose in patients with significant diarrhea despite optimal supportive care [see Dosage and Administration ( 2.5 )] . 5.3 Thrombocytopenia VONJO can cause worsening thrombocytopenia. VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre-existing moderate to severe thrombocytopenia (platelet count <100 x 10 9 /L). VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre-existing severe thrombocytopenia (platelet count <50 x 10 9 /L). Monitor platelet count prior to VONJO treatment and as clinically indicated during treatment [see Dosage and Administration ( 2.2 )] . Interrupt VONJO in patients with clinically significant worsening of thrombocytopenia that lasts for more than 7 days. Restart VONJO at 50% of the last given dose once the toxicity has resolved. If toxicity recurs hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved [see Dosage and Administration ( 2.5 )] . 5.4 Prolonged QT Interval VONJO can cause prolongation of the QTc interval. QTc prolongation of >500 msec was higher in VONJO-treated patients than in patients in the control arm (1.4% vs 1%). QTc increase from baseline by 60 msec or higher was greater in VONJO-treated patients than in control arm patients (1.9% vs 1%). Adverse reactions of QTc prolongation were reported for 3.8% of VONJO-treated patients and 2% of control arm patients. No cases of torsades de pointes were reported. Avoid use of VONJO in patients with a baseline QTc of >480 msec. Avoid use of drugs with significant potential for QTc prolongation in combination with VONJO. Correct hypokalemia prior to and during VONJO treatment. Manage QTc prolongation using VONJO interruption and electrolyte management [see Dosage and Administration ( 2.5 )] . 5.5 Major Adverse Cardiac Events (MACE) Another Janus associated kinase (JAK)-inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with VONJO particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. 5.6 Thrombosis Another JAK-inhibitor has increased the risk of thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated. Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately. 5.7 Secondary Malignancies Another JAK-inhibitor has increased the risk of lymphoma and other malignancies excluding non-melanoma skin cancer (NMSC) (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated. Patients who are current or past smokers are at additional increased risk. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with VONJO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers. 5.8 Risk of Infection Another JAK-inhibitor increased the risk of serious infections (compared to best available therapy) in patients with myeloproliferative neoplasms. Serious bacterial, mycobacterial, fungal and viral infections may occur in patients treated with VONJO. Delay starting therapy with VONJO until active serious infections have resolved. Observe patients receiving VONJO for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines. 5.9 Symptom Exacerbation Following Interruption or Discontinuation of Treatment Following discontinuation of JAK-inhibitors, including VONJO, signs and symptoms from myeloproliferative neoplasms may flare. Some patients with MF have experienced one or more of the following after discontinuing JAK-inhibitors: fever, respiratory distress, hypotension, disseminated intravascular coagulation, or multi-organ failure. If one or more of these signs and symptoms occur after discontinuation of VONJO, evaluate for and treat any intercurrent illness and consider restarting VONJO. Instruct patients not to interrupt or discontinue therapy without consulting their healthcare provider. When discontinuing or interrupting therapy with VONJO for reasons other than potentially life-threatening toxicities, consider tapering the dose of VONJO gradually rather than discontinuing abruptly [see Dosage and Administration ( 2.5 )] . 5.10 Interactions With CYP3A4 Inhibitors or Inducers Co-administration of VONJO with strong CYP3A4 inhibitors or inducers is contraindicated. Monitor for increased adverse reactions of VONJO when administered with moderate CYP3A4 inhibitors [see Contraindications ( 4 ), Drug Interactions ( 7.1 ), and Clinical Pharmacology ( 12.3 )] ."],"clinical_studies_table":["
Patient PopulationVONJO200mg Twice DailyN=31Best Available TherapyN=32
Baseline Platelets<50 × 109/L9 (29.0%)1 (3.1%)
95% Confidence Interval (CI)14.2, 48.00.1, 16.2
Difference (VONJO-BAT) 95% CI25.9 (4.3,44.5)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Pacritinib was not carcinogenic in the 6-month Tg.rasH2 transgenic mouse model. Pacritinib was not carcinogenic in a 2-year carcinogenicity study in rats at 0.004 times and 0.014 times, in males and females, respectively, the recommended human dose (AUC-based). Pacritinib exposures achieved in mice and rats during the carcinogenicity assessments were considerably lower than the exposure observed at the recommended human dose. Pacritinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in vitro in a chromosomal aberration assay (Chinese hamster ovary cells) or in vivo in a micronucleus test in mice. In a fertility study in male BALB/c mice, pacritinib was administered for at least 70 days prior to cohabitation with untreated partners. Pacritinib had no effects at any dose level on uterine implantation, macroscopic findings, reproductive organ weights, and sperm evaluations. At 213.4 mg/kg/day (3.0 times, the recommended human dose, based on body surface area), reduced mating and fertility indices were observed in male BALB/c mice. In a fertility and early embryonic development study in CD-1 mice, no effects on male or female reproductive performance, including assessments of mating, fertility, estrous cyclicity, and intrauterine survival, were observed at doses up to 250 mg/kg/day (3.0 times, the recommended human dose, based on body surface area)."],"pharmacokinetics_table":["
Hepatic impairmentRatio (90% CI) of pacritinib exposure1
Unbound CmaxUnbound AUC0-tau
Moderate impairment (Child-Pugh B)1.06(0.72, 1.58)1.05(0.69, 1.60)
Severe impairment (Child-Pugh C)1.24(0.93, 1.65)1.23(0.91, 1.66)
","
Co-administered DrugRegimen of Co-administered DrugRatio (90% CI) of pacritinib exposure 1
CmaxAUC 0-t
Clarithromycin (strong CYP3A4 inhibitor)500 mg every 12 hours for 5 days1.30(1.22, 1.39)1.80(1.67, 1.94)
Rifampin (strong CYP3A4 inducer)600 mg once daily for 10 days0.49(0.43, 0.55)0.13(0.11, 0.15)
","
Co-administered DrugRegimen of Co-administered DrugRatio (90% CI) of pacritinib exposure 1
CmaxAUC 0-tau
Fluconazole (moderate CYP3A4 inhibitor)200 mg once daily for 7 days1.41(1.35, 1.48)1.45(1.39, 1.52)
Bosentan (moderate CYP3A4 inducer)125 mg twice daily for 7 days0.84(0.76, 0.92)0.79(0.72, 0.87)
","
Co-administered DrugRegimen of Co-administered Drug (single dose)Ratio (90% CI) of exposure of co-administered drug 1
C maxAUC
Caffeine (CYP1A2 substrate)100 mg0.99(0.92, 1.07)1.22(1.12, 1.32)
Midazolam (CYP3A4 substrate)2 mg0.40(0.34, 0.46)0.40(0.35, 0.46)
Omeprazole (CYP2C19 substrate)20 mg0.73(0.46, 1.15)0.49(0.27, 0.89)
","
Co-administered DrugRegimen of Co-administered Drug (single dose)Ratio (90% CI) of exposure of co-administered drug 1
C maxAUC
Metformin (OCT1 substrate)500 mg0.96(0.87, 1.07)1.05(0.96, 1.15)
Digoxin (P-gp substrate)0.25 mg1.29(1.13, 1.47)1.15(1.05, 1.27)
Rosuvastatin (BCRP substrate)5 mg2.04(1.79, 2.31)1.80(1.63, 1.99)
"],"adverse_reactions_table":["
aGrade by CTCAE Version 4.03
Adverse ReactionsVONJO (200 mg Twice Daily) (N=106)Best Available Therapy (N=98)
All Gradesa %Grade ≥3 %All Gradesa %Grade ≥3 %
Diarrhea484150
Thrombocytopenia34322318
Nausea321111
Anemia24221514
Peripheral edema201150
Vomiting19051
Dizziness15150
Pyrexia15130
Epistaxis125131
Dyspnea10093
Pruritus10260
Upper respiratory tract infection10060
Cough82100
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION See FDA approved patient labeling ( Patient Information ). Discuss the following with the patient prior to and during treatment with VONJO: Current therapy with another kinase inhibitor Advise patients who are currently taking a kinase inhibitor that they must taper or discontinue their current kinase inhibitor therapy according to the package insert for that drug prior to starting VONJO. Hemorrhage Advise patients that VONJO can cause hemorrhage and instruct them to consult their healthcare provider right away if bleeding occurs. Advise patients about how to recognize bleeding and of the urgent need to report any unusual bleeding to their healthcare provider. Patients should urgently seek emergency medical attention for any bleeding that cannot be stopped [see Warnings and Precautions ( 5.1 )] . Diarrhea Advise patients that VONJO can cause diarrhea. Advise patients to stay hydrated while taking VONJO and to inform their healthcare provider if they experience diarrhea. Instruct patients to initiate antidiarrheal medication promptly at the first onset of symptoms (increase in frequency or change in consistency of bowel movements [loosening]) after starting VONJO. Advise patients to urgently seek emergency medical attention if diarrhea becomes severe [see Warnings and Precautions ( 5.2 )] . Thrombocytopenia Advise patients that VONJO can cause thrombocytopenia, and of the need to monitor complete blood counts before and during treatment [see Warnings and Precautions ( 5.3 )] . Prolonged QT Interval Advise patients to consult their healthcare provider immediately if they feel faint, lose consciousness, or have signs or symptoms suggestive of arrhythmia. Advise patients with a history of hypokalemia of the importance of monitoring their electrolytes [see Warnings and Precautions ( 5.4 )] . Major Adverse Cardiac Events (MACE) Advise patients that events of major adverse cardiac events (MACE) including myocardial infarction, stroke, and cardiovascular death, have been reported in clinical studies with another JAK-inhibitor used to treat rheumatoid arthritis, a condition for which VONJO is not indicated. Advise patients, especially current or past smokers or patients with other cardiovascular risk factors, to be alert for the development of signs and symptoms of cardiovascular events [see Warnings and Precautions ( 5.5 )] . Thrombosis Advise patients that events of deep vein thrombosis and pulmonary embolism have been reported in clinical studies with another JAK-inhibitor used to treat rheumatoid arthritis, a condition for which VONJO is not indicated. Advise patients to tell their healthcare provider if they develop any signs or symptoms of a DVT or PE [see Warnings and Precautions ( 5.6 )] . Secondary Malignancies Advise patients, especially current or past smokers and patients with a known secondary malignancy (other than a successfully treated NMSC), that lymphoma and other malignancies (excluding NMSC) have been reported in clinical studies with another JAK-inhibitor used to treat rheumatoid arthritis, a condition for which VONJO is not indicated [see Warnings and Precautions ( 5.7 )] . Infections Advise patients that treatment with another JAK-inhibitor has increased the risk of serious infections in patients with myeloproliferative neoplasms and that serious bacterial, mycobacterial, fungal and viral infections may occur in patients treated with VONJO. Inform patients of the signs and symptoms of infection and to report any such signs and symptoms promptly [see Warnings and Precautions ( 5.8 )] . Nausea and Vomiting Advise patients that nausea and vomiting may occur during treatment with VONJO. Instruct them on how to manage nausea and vomiting and to immediately inform their healthcare provider if nausea/vomiting become severe. Symptom Exacerbation Following Interruption or Discontinuation of Treatment with VONJO Inform patients that after discontinuation of treatment, signs and symptoms from myeloproliferative neoplasms may flare. Instruct patients not to interrupt or discontinue VONJO therapy without consulting their healthcare provider [see Warnings and Precautions ( 5.9 )] . Drug–Drug Interactions Advise patients to inform their healthcare providers of all medications they are taking, including prescription and over-the-counter medications, vitamins, herbal products, and dietary supplements [see Drug Interactions ( 7 )] . Inform women of the possible reduced effectiveness of hormonal contraceptives when under treatment with VONJO and for 30 days after last dose. Advise women of childbearing potential receiving VONJO and hormonal contraception, to use additional nonhormonal contraception or use an alternative contraceptive that is not affected by CYP3A4 inducers [see Drug Interactions ( 7.2 )] . Dosing Advise patients to take VONJO twice a day, with or without food or drink. VONJO should be taken at similar times each day. Instruct patients to swallow the VONJO capsules whole and not to open, break, or chew the capsules [see Dosage and Administration ( 2.1 )] . Instruct patients that if they miss a dose of VONJO, to skip the dose and take the next dose when it is due and return to the normal schedule [see Dosage and Administration ( 2.1 )]. Warn patients not to take 2 doses to make up for the missed dose. Instruct patients to discontinue VONJO 7 days prior to any surgery or invasive procedures (such as cardiac catheterization, coronary stenting or varicose vein ablation) due to the risk of bleeding and to only restart VONJO on the instruction of their healthcare provider. Patients should not change or stop taking VONJO without first consulting their healthcare provider. Lactation Advise patients to avoid breastfeeding while taking VONJO and for 2 weeks after the final dose [see Use in Specific Populations ( 8.2 )] . Manufactured and marketed by: Sobi, Inc. 77 4th Ave, FL 3 Waltham, MA, 02451 SOBI VONJO ® is a registered trademark of Sobi Inc. All rights reserved. ©2022 All rights reserved."],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended dosage is 200 mg orally twice daily ( 2.1 ). May be taken with or without food ( 2.1 ). 2.1 Recommended Dosage The recommended dosage of VONJO is 200 mg orally twice daily. VONJO may be taken with or without food. Swallow capsules whole. Do not open, break, or chew capsules. Patients who are on treatment with other kinase inhibitors before the initiation of VONJO must taper or discontinue according to the prescribing information for that drug. 2.2 Monitoring for Safety Perform a complete blood count (CBC; including white blood cell count differential and platelet count), coagulation testing (prothrombin time, partial thromboplastin time, thrombin time, and international normalized ratio) and a baseline electrocardiogram (ECG), prior to starting VONJO, and monitor as clinically indicated while the patient is on treatment. 2.3 Missed Dose If a dose of VONJO is missed, the patient should take the next prescribed dose at its scheduled time. Extra capsules should not be taken to make up for the missed dose. 2.4 Dose Interruption for Planned Surgical Procedures or Other Interventions Discontinue VONJO 7 days prior to elective surgery or invasive procedures because of the risk of hemorrhage and restart only after hemostasis is assured. 2.5 Dose Modification for Adverse Reactions Dose modifications for diarrhea, thrombocytopenia, hemorrhage, and prolonged QT interval are described in Table 1 , Table 2 , Table 3 , and Table 4 respectively. See Warning and Precautions ( 5.1 , 5.2 , 5.3 , and 5.4 ) for additional risk minimization recommendations. Dose levels for VONJO are as follows: 200 mg twice daily (initial starting dose), 100 mg twice daily (first dose reduction), 100 mg once daily (second dose reduction). Discontinue VONJO in patients unable to tolerate a dose of 100 mg daily. Table 1 Dosage Modification for Diarrhea Toxicity Management/Action a Increase of at least 7 stools per day over baseline, or hospitalization indicated, or severe increase in ostomy output over baseline, or if limiting self-care. b Increase of <4 stools per day over baseline or mild increase in ostomy output compared to baseline. New onset of diarrhea Initiate anti-diarrheal medications. Encourage adequate oral hydration. Grade 3 or 4 a Hold VONJO until the diarrhea resolves to Grade 1 b or lower or baseline. Restart VONJO at the last given dose. Intensify anti-diarrheal regimen. Provide fluid replacement. If diarrhea recurs, hold VONJO until the diarrhea resolves to Grade 1 b or lower or baseline. Restart VONJO at 50% of the last given dose once the toxicity has resolved. Concomitant antidiarrheal treatment is required for patients restarting VONJO. Table 2 Dose Modification for Thrombocytopenia Worsening Thrombocytopenia Action For clinically significant worsening of thrombocytopenia that lasts more than 7 days Hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved. If toxicity recurs hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved. Table 3 Dose Modification for Hemorrhage Toxicity Action Moderate bleeding; intervention indicated Hold VONJO until hemorrhage resolves. Restart VONJO at the last given dose. If hemorrhage recurs, hold VONJO until resolution then restart at 50% of the last given dose. Severe bleeding; transfusion, invasive intervention, or hospitalization indicated Hold VONJO until hemorrhage resolves. Restart VONJO at 50% of the last given dose. If bleeding recurs, discontinue VONJO. Life-threatening bleeding; urgent intervention indicated. Discontinue VONJO. Table 4 Dose Modification for Prolonged QT Interval Toxicity Action QTc prolongation >500 msec or >60 msec from baseline Hold VONJO. If QTc prolongation resolves to ≤480 msec or baseline within 1 week, restart VONJO at the same dose. If time to resolution is greater than 1 week, restart VONJO at a reduced dose. 2.6 Dosage Modification for Patients with Severe Hepatic Impairment The recommended dosage of VONJO in patients with severe hepatic impairment [Child-Pugh C] is 100 mg twice daily. Dosage may be increased to 200 mg twice daily if the treatment is not effective after 12 weeks and there are no safety concerns; continue monitoring for safety [see Use in Specific Populations ( 8.6 ) and Clinical Pharmacology ( 12.3 )]."],"spl_product_data_elements":["Vonjo Pacritinib MICROCRYSTALLINE CELLULOSE POLYETHYLENE GLYCOL 8000 MAGNESIUM STEARATE GELATIN, UNSPECIFIED PACRITINIB PACRITINIB Gray Red Capsule Pacritinib;100mg;C78837"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Capsule: 100 mg, oblong, size 0 hard gelatin capsule with an opaque scarlet cap printed with “Pacritinib 100 mg” and opaque gray body printed with “C78837”. Capsules: 100 mg ( 3 )"],"spl_patient_package_insert":["PATIENT INFORMATION VONJO (VON-joh) (pacritinib) capsules What is VONJO? VONJO is a prescription medicine used to treat adults with certain types of myelofibrosis who have a platelet count below 50 x 10 9 /L. It is not known if VONJO is safe and effective in children. Before taking VONJO, tell your healthcare provider about all of your medical conditions, including if you: have active bleeding, have had severe bleeding, or plan to have surgery or invasive procedures. You should stop taking VONJO 7 days before any planned surgery or invasive procedures. See “ What are the possible side effects of VONJO? ” have diarrhea or commonly have loose stools have had a blood clot, heart attack, other heart problems, or stroke have a history of low blood levels of potassium. It is important that you get blood tests done during treatment with VONJO to monitor your body salts (electrolytes). smoke or were a smoker in the past have had any other cancers. See “ What are the possible side effects of VONJO? ” have an infection. See “What are the possible side effects of VONJO?” have nausea or vomiting have liver or kidney problems are pregnant or plan to become pregnant. It is not known if VONJO will harm your unborn baby are breastfeeding or plan to breastfeed. It is not known if VONJO passes into your breast milk. You should not breastfeed during treatment and for 2 weeks after your last dose of VONJO. Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking VONJO with certain other medicines may affect the amount of VONJO or the other medicines in your blood and may increase your risk of side effects or affect how well VONJO works. Especially tell your healthcare provider if you take hormonal contraceptives (birth control). Hormonal birth control methods, except for intrauterine systems containing levonorgestrel may not work during treatment with VONJO and for 30 days after your last dose. Talk to your healthcare provider about birth control methods that may be right for you during treatment with VONJO. Know the medicines you take. Keep a list of the medicines you take to show your healthcare provider and pharmacist when you get a new medicine. How should I take VONJO? Take VONJO exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking VONJO without first talking to your healthcare provider. If you stop treatment with VONJO, symptoms of your condition may return. See “What are the possible side effects of VONJO?” If you take other kinase inhibitors, carefully follow your healthcare provider's instructions about how to slowly decrease (taper) your dose or stop the other kinase inhibitor medicines before you begin taking VONJO. VONJO is usually taken by mouth 2 times each day. Swallow VONJO capsules whole. Do not open, break, or chew capsules. You can take VONJO with or without food or drink. Take your VONJO doses at about the same time every day. If you notice any change in how often you have bowel movements, if they become softer or you have diarrhea, start taking an antidiarrheal medicine (for example, loperamide) as soon as you notice changes, as directed by your healthcare provider. If you miss a dose of VONJO, skip the dose and just take your next dose at your regularly scheduled time. Do not take 2 doses at the same time to make up for the missed dose. If you take too much VONJO, call your healthcare provider or go to the nearest emergency room right away and take your bottle of VONJO with you. What are the possible side effects of VONJO? VONJO can cause serious side effects including: Bleeding. VONJO can cause severe bleeding, which can be serious and, in some cases may lead to death. Stop taking VONJO and tell your healthcare provider right away if you develop any of these symptoms: unusual bleeding, bruising, and fever. Get medical help right away for any bleeding that you cannot stop. You will need to stop taking VONJO 7 days before any planned surgery or invasive procedure (such as a heart catheterization, stent placement in a coronary artery in your heart, or a procedure for varicose veins). Your healthcare provider should tell you when you can start taking VONJO again. Diarrhea. Diarrhea is common with VONJO, but can also be severe, and cause loss of too much body fluid (dehydration). Dehydration can lead to kidney problems. Tell your healthcare provider if you develop diarrhea during treatment with VONJO. Drink plenty of fluids to help prevent dehydration. Your healthcare provider will prescribe an anti-diarrheal medicine before you start VONJO. You should start taking the anti-diarrheal medicine right away if you get any symptoms of diarrhea, including any changes in consistency (such as loose stools) or increase in the number of daily bowel movements, during treatment with VONJO. Get emergency medical help right away if your diarrhea becomes severe. Worsening low platelet counts . Changes in the electrical activity of your heart called QTc prolongation . QTc prolongation can cause irregular heartbeats that can be life-threatening. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint. Increased risk of major cardiovascular events such as heart attack, stroke, or death in people have happened, especially in those who have cardiovascular risk factors and who are current or past smokers taking another Janus Kinase (JAK)-inhibitor to treat rheumatoid arthritis. Get emergency help right away if you have any symptoms of a heart attack or stroke during treatment with VONJO, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on one side of your body slurred speech Increased risk of blood clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in some people taking another JAK-inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with VONJO, including: swelling, pain, or tenderness in one or both legs sudden, unexplained chest pain shortness of breath or difficulty breathing Possible increased risk of new (secondary) cancers. People who take another JAK-inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers, except non-melanoma skin cancer. The risk of new cancers is further increased in people who smoke or who smoked in the past. Risk of infection. People who have certain blood cancers and take another JAK-inhibitor have an increased risk of serious infections. People who take VONJO may also develop serious infections, including bacterial, mycobacterial, fungal, and viral infections. If you have a serious infection, your healthcare provider may not start you on VONJO until your infection is gone. Your healthcare provider will monitor you and treat you for any infections that you get during treatment with VONJO. Tell your healthcare provider right away if you develop any of the following symptoms of infection : o chills o vomiting o aches o weakness o fever o painful skin rash or blisters o nausea • Worsening of symptoms after interrupting or stopping treatment. Signs and symptoms of myelofibrosis may worsen after you stop treatment with VONJO. Do not interrupt or stop treatment with VONJO without talking to your healthcare provider. If you need to stop treatment with VONJO, your healthcare provider may give you instructions for slowly stopping treatment. Tell your healthcare provider right away if you get any of the following signs and symptoms after stopping treatment with VONJO: o fever o weakness o trouble breathing o night sweats o feeling dizzy or lightheaded o pain in your left upper stomach (abdomen) area or left shoulder The most common side effects of VONJO include: low platelet counts nausea and vomiting low red blood cell counts (anemia) swelling of your ankles, legs, and feet Your healthcare provider will do blood tests and an electrocardiogram (ECG) before you start treatment with VONJO and as needed during treatment to check for side effects. Your healthcare provider may change your dose or how often you take VONJO, temporarily stop or permanently stop treatment with VONJO if you have certain side effects. VONJO may affect fertility in males. You may have problems fathering a child. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects with VONJO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store VONJO? Store VONJO at room temperature, below 86°F (30°C). Store VONJO in the original package. Keep the bottle tightly closed to protect VONJO from light. Keep VONJO and all medicines out of the reach of children. General information about the safe and effective use of VONJO. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VONJO for a condition for which it was not prescribed. Do not give VONJO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VONJO that is written for health professionals. What are the ingredients in VONJO? Active ingredient: pacritinib Inactive ingredients: microcrystalline cellulose, polyethylene glycol 8000 (PEG 8000), and magnesium stearate. The capsule shell contains gelatin, titanium dioxide, black iron oxide, erythrosine, red iron oxide, and printing ink containing shellac, propylene glycol, titanium dioxide, sodium hydroxide, and povidone. Manufactured and Marketed by: Sobi Inc., 77 4th Ave, FL 3, Waltham, MA, 02451 VONJO ® is a registered trademark of Sobi Inc. All rights reserved. For more information call (866) 773-5274 or go to www.VONJO.com. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 03/2026"],"clinical_pharmacology_table":["
Hepatic impairmentRatio (90% CI) of pacritinib exposure1
Unbound CmaxUnbound AUC0-tau
Moderate impairment (Child-Pugh B)1.06(0.72, 1.58)1.05(0.69, 1.60)
Severe impairment (Child-Pugh C)1.24(0.93, 1.65)1.23(0.91, 1.66)
","
Co-administered DrugRegimen of Co-administered DrugRatio (90% CI) of pacritinib exposure 1
CmaxAUC 0-t
Clarithromycin (strong CYP3A4 inhibitor)500 mg every 12 hours for 5 days1.30(1.22, 1.39)1.80(1.67, 1.94)
Rifampin (strong CYP3A4 inducer)600 mg once daily for 10 days0.49(0.43, 0.55)0.13(0.11, 0.15)
","
Co-administered DrugRegimen of Co-administered DrugRatio (90% CI) of pacritinib exposure 1
CmaxAUC 0-tau
Fluconazole (moderate CYP3A4 inhibitor)200 mg once daily for 7 days1.41(1.35, 1.48)1.45(1.39, 1.52)
Bosentan (moderate CYP3A4 inducer)125 mg twice daily for 7 days0.84(0.76, 0.92)0.79(0.72, 0.87)
","
Co-administered DrugRegimen of Co-administered Drug (single dose)Ratio (90% CI) of exposure of co-administered drug 1
C maxAUC
Caffeine (CYP1A2 substrate)100 mg0.99(0.92, 1.07)1.22(1.12, 1.32)
Midazolam (CYP3A4 substrate)2 mg0.40(0.34, 0.46)0.40(0.35, 0.46)
Omeprazole (CYP2C19 substrate)20 mg0.73(0.46, 1.15)0.49(0.27, 0.89)
","
Co-administered DrugRegimen of Co-administered Drug (single dose)Ratio (90% CI) of exposure of co-administered drug 1
C maxAUC
Metformin (OCT1 substrate)500 mg0.96(0.87, 1.07)1.05(0.96, 1.15)
Digoxin (P-gp substrate)0.25 mg1.29(1.13, 1.47)1.15(1.05, 1.27)
Rosuvastatin (BCRP substrate)5 mg2.04(1.79, 2.31)1.80(1.63, 1.99)
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed ( 8.2 ). Hepatic Impairment: For patients with severe hepatic impairment (Child-Pugh C), the recommended dosage is 100 mg twice daily ( 8.6 ). Renal Impairment: Avoid use in patients with eGFR <30 mL/min ( 8.7 ). 8.1 Pregnancy Risk Summary There are no available data on VONJO use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, administration of pacritinib to pregnant mice or rabbits at exposures that were considerably lower than those observed at the recommended human dose were associated with maternal toxicity and embryonic and fetal loss (see Data ) . Advise pregnant women of the potential risk to a fetus. Consider the benefits and risks of VONJO for the mother and possible risks to the fetus when prescribing VONJO to a pregnant woman. The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Pacritinib was administered orally to pregnant mice at doses of 30, 100, or 250 mg/kg/day from gestation day 6 to gestation day 15. Pacritinib was also administered orally to pregnant rabbits at doses of 15, 30, or 60 mg/kg/day from gestation day 7 until gestation day 20. In both species, pacritinib was associated with maternal toxicity, which resulted in post-implantation loss in mice, abortions in rabbits, and reduced fetal body weights in mice and rabbits at exposures 0.1 times (mice) and 0.3 times (rabbits) the exposure at the recommended human dose (AUC-based). In mice, the high dose was associated with an increased incidence of an external malformation (cleft palate) in the presence of maternal toxicity. In a pre- and post-natal development study in mice, pregnant animals were dosed with pacritinib from implantation through lactation at 30, 100, or 250 mg/kg/day. Maternal toxicity was noted at 250 mg/kg and associated with increased gestation length and dystocia, lowered mean birth weights and neonatal survival, and transiently delayed startle response, learning, and memory development at weaning. 8.2 Lactation Risk Summary There are no data on the presence of pacritinib in either human or animal milk, the effects on the breastfed child, or the effects on milk production. It is not known whether VONJO is excreted in human milk. Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with VONJO, and for 2 weeks after the last dose. 8.3 Females and Males of Reproductive Potential Infertility Males Pacritinib reduced male mating and fertility indices in BALB/c mice [see Nonclinical Toxicology ( 13.1 )]. Pacritinib may impair male fertility in humans. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of VONJO did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. 8.6 Hepatic Impairment In patients with severe hepatic impairment [Child-Pugh C], the recommended dosage of VONJO is 100 mg twice daily. Dosage may be increased to 200 mg twice daily if the treatment is not effective after 12 weeks and there are no safety concerns. Monitor hepatically-impaired patients for adverse reactions and consider VONJO dose modifications based on safety and efficacy [see Dosage and Administration (2.5), Clinical Pharmacology ( 12.3 )]. No dose modification is recommended for patients with mild [Child-Pugh A] or moderate [Child-Pugh B] hepatic impairment [see Clinical Pharmacology ( 12.3 )]. 8.7 Renal Impairment Administration of a single dose of VONJO 400 mg to subjects with renal impairment resulted in approximately 30% increase in C max and AUC of pacritinib in subjects with eGFR 15 to 29 mL/min and eGFR <15 mL/min on hemodialysis compared to subjects with normal renal function (eGFR ≥90 mL/min). Avoid use of VONJO in patients with eGFR <30 mL/min [see Clinical Pharmacology ( 12.3 )] ."],"dosage_and_administration_table":["
ToxicityManagement/Action
aIncrease of at least 7 stools per day over baseline, or hospitalization indicated, or severe increase in ostomy output over baseline, or if limiting self-care.
bIncrease of <4 stools per day over baseline or mild increase in ostomy output compared to baseline.
New onset of diarrheaInitiate anti-diarrheal medications.Encourage adequate oral hydration.
Grade 3 or 4 aHold VONJO until the diarrhea resolves to Grade 1b or lower or baseline. Restart VONJO at the last given dose.Intensify anti-diarrheal regimen. Provide fluid replacement.If diarrhea recurs, hold VONJO until the diarrhea resolves to Grade 1b or lower or baseline. Restart VONJO at 50% of the last given dose once the toxicity has resolved.Concomitant antidiarrheal treatment is required for patients restarting VONJO.
","
Worsening ThrombocytopeniaAction
For clinically significant worsening of thrombocytopenia that lasts more than 7 daysHold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved.If toxicity recurs hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved.
","
ToxicityAction
Moderate bleeding; intervention indicatedHold VONJO until hemorrhage resolves. Restart VONJO at the last given dose.If hemorrhage recurs, hold VONJO until resolution then restart at 50% of the last given dose.
Severe bleeding; transfusion, invasive intervention, or hospitalization indicatedHold VONJO until hemorrhage resolves.Restart VONJO at 50% of the last given dose.If bleeding recurs, discontinue VONJO.
Life-threatening bleeding; urgent intervention indicated.Discontinue VONJO.
","
ToxicityAction
QTc prolongation >500 msec or >60 msec from baselineHold VONJO.If QTc prolongation resolves to ≤480 msec or baseline within 1 week, restart VONJO at the same dose.If time to resolution is greater than 1 week, restart VONJO at a reduced dose.
"],"spl_patient_package_insert_table":["
PATIENT INFORMATION VONJO (VON-joh) (pacritinib) capsules
What is VONJO?VONJO is a prescription medicine used to treat adults with certain types of myelofibrosis who have a platelet count below 50 x 10 9/L.It is not known if VONJO is safe and effective in children.
Before taking VONJO, tell your healthcare provider about all of your medical conditions, including if you:have active bleeding, have had severe bleeding, or plan to have surgery or invasive procedures. You should stop taking VONJO 7 days before any planned surgery or invasive procedures. See “What are the possible side effects of VONJO?”have diarrhea or commonly have loose stoolshave had a blood clot, heart attack, other heart problems, or strokehave a history of low blood levels of potassium. It is important that you get blood tests done during treatment with VONJO to monitor your body salts (electrolytes).smoke or were a smoker in the pasthave had any other cancers. See “What are the possible side effects of VONJO?”have an infection. See “What are the possible side effects of VONJO?” have nausea or vomitinghave liver or kidney problemsare pregnant or plan to become pregnant. It is not known if VONJO will harm your unborn babyare breastfeeding or plan to breastfeed. It is not known if VONJO passes into your breast milk. You should not breastfeed during treatment and for 2 weeks after your last dose of VONJO. Talk to your healthcare provider about the best way to feed your baby during this time.Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking VONJO with certain other medicines may affect the amount of VONJO or the other medicines in your blood and may increase your risk of side effects or affect how well VONJO works.Especially tell your healthcare provider if you take hormonal contraceptives (birth control). Hormonal birth control methods, except for intrauterine systems containing levonorgestrel may not work during treatment with VONJO and for 30 days after your last dose. Talk to your healthcare provider about birth control methods that may be right for you during treatment with VONJO.Know the medicines you take. Keep a list of the medicines you take to show your healthcare provider and pharmacist when you get a new medicine.
How should I take VONJO?Take VONJO exactly as your healthcare provider tells you to take it.Do not change your dose or stop taking VONJO without first talking to your healthcare provider. If you stop treatment with VONJO, symptoms of your condition may return. See “What are the possible side effects of VONJO?”If you take other kinase inhibitors, carefully follow your healthcare provider's instructions about how to slowly decrease (taper) your dose or stop the other kinase inhibitor medicines before you begin taking VONJO.VONJO is usually taken by mouth 2 times each day.Swallow VONJO capsules whole. Do not open, break, or chew capsules.You can take VONJO with or without food or drink.Take your VONJO doses at about the same time every day.If you notice any change in how often you have bowel movements, if they become softer or you have diarrhea, start taking an antidiarrheal medicine (for example, loperamide) as soon as you notice changes, as directed by your healthcare provider.If you miss a dose of VONJO, skip the dose and just take your next dose at your regularly scheduled time. Do not take 2 doses at the same time to make up for the missed dose.If you take too much VONJO, call your healthcare provider or go to the nearest emergency room right away and take your bottle of VONJO with you.
What are the possible side effects of VONJO?VONJO can cause serious side effects including:Bleeding.VONJO can cause severe bleeding, which can be serious and, in some cases may lead to death. Stop taking VONJO and tell your healthcare provider right away if you develop any of these symptoms: unusual bleeding, bruising, and fever. Get medical help right away for any bleeding that you cannot stop. You will need to stop taking VONJO 7 days before any planned surgery or invasive procedure (such as a heart catheterization, stent placement in a coronary artery in your heart, or a procedure for varicose veins). Your healthcare provider should tell you when you can start taking VONJO again.Diarrhea.Diarrhea is common with VONJO, but can also be severe, and cause loss of too much body fluid (dehydration). Dehydration can lead to kidney problems. Tell your healthcare provider if you develop diarrhea during treatment with VONJO. Drink plenty of fluids to help prevent dehydration. Your healthcare provider will prescribe an anti-diarrheal medicine before you start VONJO. You should start taking the anti-diarrheal medicine right away if you get any symptoms of diarrhea, including any changes in consistency (such as loose stools) or increase in the number of daily bowel movements, during treatment with VONJO. Get emergency medical help right away if your diarrhea becomes severe.Worsening low platelet counts.Changes in the electrical activity of your heart called QTc prolongation. QTc prolongation can cause irregular heartbeats that can be life-threatening. Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint.Increased risk of major cardiovascular events such as heart attack, stroke, or death in people have happened, especially in those who have cardiovascular risk factors and who are current or past smokers taking another Janus Kinase (JAK)-inhibitor to treat rheumatoid arthritis. Get emergency help right away if you have any symptoms of a heart attack or stroke during treatment with VONJO, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes backsevere tightness, pain, pressure, or heaviness in your chest, throat, neck, or jawpain or discomfort in your arms, back, neck, jaw, or stomachshortness of breath with or without chest discomfortbreaking out in a cold sweatnausea or vomitingfeeling lightheadedweakness in one part or on one side of your bodyslurred speechIncreased risk of blood clots.Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in some people taking another JAK-inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with VONJO, including:swelling, pain, or tenderness in one or both legssudden, unexplained chest painshortness of breath or difficulty breathingPossible increased risk of new (secondary) cancers.People who take another JAK-inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers, except non-melanoma skin cancer. The risk of new cancers is further increased in people who smoke or who smoked in the past.Risk of infection.People who have certain blood cancers and take another JAK-inhibitor have an increased risk of serious infections. People who take VONJO may also develop serious infections, including bacterial, mycobacterial, fungal, and viral infections. If you have a serious infection, your healthcare provider may not start you on VONJO until your infection is gone. Your healthcare provider will monitor you and treat you for any infections that you get during treatment with VONJO.Tell your healthcare provider right away if you develop any of the following symptoms of infection: o chills o vomiting o aches o weakness o fever o painful skin rash or blisters o nausea • Worsening of symptoms after interrupting or stopping treatment. Signs and symptoms of myelofibrosis may worsen after you stop treatment with VONJO. Do not interrupt or stop treatment with VONJO without talking to your healthcare provider. If you need to stop treatment with VONJO, your healthcare provider may give you instructions for slowly stopping treatment. Tell your healthcare provider right away if you get any of the following signs and symptoms after stopping treatment with VONJO: o fever o weakness o trouble breathing o night sweats o feeling dizzy or lightheaded o pain in your left upper stomach (abdomen) area or left shoulderThe most common side effects of VONJO include:low platelet countsnausea and vomitinglow red blood cell counts (anemia)swelling of your ankles, legs, and feetYour healthcare provider will do blood tests and an electrocardiogram (ECG) before you start treatment with VONJO and as needed during treatment to check for side effects.Your healthcare provider may change your dose or how often you take VONJO, temporarily stop or permanently stop treatment with VONJO if you have certain side effects.VONJO may affect fertility in males. You may have problems fathering a child. Talk to your healthcare provider if this is a concern for you.These are not all of the possible side effects with VONJO.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store VONJO?Store VONJO at room temperature, below 86°F (30°C).Store VONJO in the original package.Keep the bottle tightly closed to protect VONJO from light.Keep VONJO and all medicines out of the reach of children.
General information about the safe and effective use of VONJO.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use VONJO for a condition for which it was not prescribed. Do not give VONJO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about VONJO that is written for health professionals.
What are the ingredients in VONJO?Active ingredient: pacritinibInactive ingredients: microcrystalline cellulose, polyethylene glycol 8000 (PEG 8000), and magnesium stearate. The capsule shell contains gelatin, titanium dioxide, black iron oxide, erythrosine, red iron oxide, and printing ink containing shellac, propylene glycol, titanium dioxide, sodium hydroxide, and povidone.Manufactured and Marketed by: Sobi Inc., 77 4th Ave, FL 3, Waltham, MA, 02451VONJO® is a registered trademark of Sobi Inc. All rights reserved.For more information call (866) 773-5274 or go to www.VONJO.com.
"],"package_label_principal_display_panel":["Principal Display Panel - 100 mg Carton Label NDC 72482- 100 -12 Rx only VONJO ® (pacritinib) capsules 100 mg 120 capsules Swallow capsules whole. Do not open, break, or chew capsules. Keep out of the sight and reach of children. image description","Principal Display Panel - 100 mg Bottle Label NDC 72482- 100 -12 Rx only VONJO ® (pacritinib) capsules 100 mg 120 capsules Swallow capsules whole. Do not open, break, or chew capsules. Keep out of the sight and reach of children. image description","Principal Display Panel - 100 mg Carton Label NDC 72482- 100 -12 Rx only VONJO ® (pacritinib) capsules 100 mg 120 capsules Swallow capsules whole. Do not open, break, or chew capsules. Keep out of the sight and reach of children. image description","Principal Display Panel - 100 mg Bottle Label NDC 72482- 100 -12 Rx only VONJO ® (pacritinib) capsules 100 mg 120 capsules Swallow capsules whole. Do not open, break, or chew capsules. Keep out of the sight and reach of children. image description"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility Pacritinib was not carcinogenic in the 6-month Tg.rasH2 transgenic mouse model. Pacritinib was not carcinogenic in a 2-year carcinogenicity study in rats at 0.004 times and 0.014 times, in males and females, respectively, the recommended human dose (AUC-based). Pacritinib exposures achieved in mice and rats during the carcinogenicity assessments were considerably lower than the exposure observed at the recommended human dose. Pacritinib was not mutagenic in a bacterial mutagenicity assay (Ames test) or clastogenic in vitro in a chromosomal aberration assay (Chinese hamster ovary cells) or in vivo in a micronucleus test in mice. In a fertility study in male BALB/c mice, pacritinib was administered for at least 70 days prior to cohabitation with untreated partners. Pacritinib had no effects at any dose level on uterine implantation, macroscopic findings, reproductive organ weights, and sperm evaluations. At 213.4 mg/kg/day (3.0 times, the recommended human dose, based on body surface area), reduced mating and fertility indices were observed in male BALB/c mice. In a fertility and early embryonic development study in CD-1 mice, no effects on male or female reproductive performance, including assessments of mating, fertility, estrous cyclicity, and intrauterine survival, were observed at doses up to 250 mg/kg/day (3.0 times, the recommended human dose, based on body surface area)."]},"tags":[{"label":"Kinase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Tyrosine-protein kinase JAK2","category":"target"},{"label":"JAK2","category":"gene"},{"label":"FLT3","category":"gene"},{"label":"STK11","category":"gene"},{"label":"L01EJ03","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Myelofibrosis","category":"indication"},{"label":"Sobi","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"578 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"533 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"348 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"301 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"276 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"266 reports"},{"date":"","signal":"PLATELET COUNT DECREASED","source":"FDA FAERS","actionTaken":"261 reports"},{"date":"","signal":"HAEMOGLOBIN DECREASED","source":"FDA FAERS","actionTaken":"195 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"138 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"109 reports"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"48%","severity":"common","_validated":true},{"effect":"Thrombocytopenia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Nausea","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Anemia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Peripheral edema","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Vomiting","drugRate":"19%","severity":"mild","_validated":true},{"effect":"Dizziness","drugRate":"15%","severity":"mild","_validated":true},{"effect":"Pyrexia","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Epistaxis","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Dyspnea","drugRate":"10%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Upper respiratory tract infection","drugRate":"10%","severity":"mild","_validated":true},{"effect":"Cough","drugRate":"","severity":"mild","_validated":false,"_confidence":0.3},{"effect":"Pneumonia","drugRate":"6%","severity":"serious","_validated":true},{"effect":"Cardiac failure","drugRate":"4%","severity":"serious","_validated":true},{"effect":"Disease progression","drugRate":"3%","severity":"serious","_validated":true},{"effect":"Squamous cell carcinoma of skin","drugRate":"3%","severity":"serious","_validated":true},{"effect":"Neutropenia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Conjunctival hemorrhage","drugRate":"2%","severity":"mild","_validated":true}],"contraindications":["Drug inhibition of cytochrome p450 CYP3A enzyme"],"specialPopulations":{"Lactation":"It is not known whether VONJO is excreted in human milk. Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with VONJO, and for weeks after the last dose.","Pregnancy":"There are no available data on VONJO use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. In animal reproduction studies, administration of pacritinib to pregnant mice or rabbits at exposures that were considerably lower than those observed at the recommended human dose were associated with maternal toxicity and embryonic and fetal loss (see Data). Advise pregnant women of the potential risk to fetus. Consider the benefits and risks of VONJO for the mother and possible risks to the fetus when prescribing VONJO to pregnant woman.","Geriatric use":"Clinical studies of VONJO did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established.","Renal impairment":"Avoid use in patients with eGFR <30 mL/min","Hepatic impairment":"Avoid use in moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C)"}},"trials":[],"aliases":[],"company":"Sobi","patents":[{"applNo":"N208712","source":"FDA Orange Book","status":"Active","expires":"May 5, 2028","useCode":"U-3332","territory":"US","drugProduct":false,"patentNumber":"9573964","drugSubstance":false},{"applNo":"N208712","source":"FDA Orange Book","status":"Active","expires":"Jan 17, 2029","useCode":"U-3332","territory":"US","drugProduct":true,"patentNumber":"8153632","drugSubstance":true},{"applNo":"N208712","source":"FDA Orange Book","status":"Active","expires":"Mar 25, 2030","useCode":"U-3331","territory":"US","drugProduct":true,"patentNumber":"8980873","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PACRITINIB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:44:14.478928+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:44:14.478640+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:44:22.140980+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:44:13.027926+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:44:22.958245+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:12.051693+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:12.051748+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:12.051763+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:44:24.481501+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4778465/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:44:23.445887+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA208712","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:44:12.051772+00:00"}},"allNames":"vonjo","offLabel":[],"synonyms":["pacritinib","pacritinib citrate","vonjo","SB1518","SB-1518"],"timeline":[{"date":"2022-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from MARINUS PHARMA INC to Sobi"},{"date":"2022-03-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Marinus Pharma Inc)"},{"date":"2027-02-28","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2029-01-17","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8153632 expires"},{"date":"2029-02-28","type":"negative","source":"FDA Orange Book","milestone":"ODE-397 exclusivity expires"},{"date":"2030-03-25","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8980873 expires"}],"aiSummary":"Vonjo (Pacritinib) is a small molecule kinase inhibitor developed by Marinus Pharma Inc and currently owned by Sobi. It targets the Tyrosine-protein kinase JAK2, a key enzyme involved in the signaling pathways that regulate blood cell production. Vonjo is FDA-approved for the treatment of myelofibrosis, a type of bone marrow disorder. The drug is patented and not yet available as a generic. Key safety considerations include the potential for gastrointestinal and hematologic adverse effects.","approvals":[{"date":"2022-03-18","orphan":true,"company":"MARINUS PHARMA INC","regulator":"FDA"}],"brandName":"Vonjo","ecosystem":[{"indication":"Myelofibrosis","otherDrugs":[{"name":"fedratinib","slug":"fedratinib","company":"Impact"},{"name":"ruxolitinib","slug":"ruxolitinib","company":"Incyte Corp"}],"globalPrevalence":240000}],"mechanism":{"target":"Tyrosine-protein kinase JAK2","novelty":"Follow-on","targets":[{"gene":"JAK2","source":"DrugCentral","target":"Tyrosine-protein kinase JAK2","protein":"Tyrosine-protein kinase JAK2"},{"gene":"FLT3","source":"DrugCentral","target":"Receptor-type tyrosine-protein kinase FLT3","protein":"Receptor-type tyrosine-protein kinase FLT3"},{"gene":"STK11","source":"DrugCentral","target":"Serine/threonine-protein kinase STK11","protein":"Serine/threonine-protein kinase STK11"},{"gene":"NQO2","source":"DrugCentral","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]"},{"gene":"ACVR1","source":"DrugCentral","target":"Activin receptor type-1","protein":"Activin receptor type-1"},{"gene":"ADCK1","source":"DrugCentral","target":"Uncharacterized aarF domain-containing protein kinase 1","protein":"Uncharacterized aarF domain-containing protein kinase 1"},{"gene":"IRAK3","source":"DrugCentral","target":"Interleukin-1 receptor-associated kinase 3","protein":"Interleukin-1 receptor-associated kinase 3"},{"gene":"TYK2","source":"DrugCentral","target":"Non-receptor tyrosine-protein kinase TYK2","protein":"Non-receptor tyrosine-protein kinase TYK2"},{"gene":"BMP2K","source":"DrugCentral","target":"BMP-2-inducible protein kinase","protein":"BMP-2-inducible protein kinase"},{"gene":"AAK1","source":"DrugCentral","target":"AP2-associated protein kinase 1","protein":"AP2-associated protein kinase 1"}],"moaClass":"Breast Cancer Resistance Protein Inhibitors","modality":"Small Molecule","drugClass":"Kinase Inhibitor [EPC]","explanation":"Pacritinib is an oral kinase inhibitor with activity against wild type Janus associated kinase (JAK2), mutant JAK2V617F, and FMS-like tyrosine kinase (FLT3), which contribute to signaling of number of cytokines and growth factors that are important for hematopoiesis and immune function. MF is often associated with dysregulated JAK2 signaling. Pacritinib has higher inhibitory activity for JAK2 compared to JAK3 and TYK2. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1) the clinical relevance of which is unknown.","oneSentence":"Vonjo works by blocking the activity of the JAK2 enzyme, which is overactive in myelofibrosis patients.","technicalDetail":"Pacritinib selectively inhibits the JAK2 kinase, which is involved in the signaling pathways that regulate hematopoiesis and is overexpressed in myelofibrosis patients, leading to the aberrant proliferation of megakaryocytes and fibrosis in the bone marrow."},"commercial":{"launchDate":"2022","_launchSource":"DrugCentral (FDA 2022-03-18, MARINUS PHARMA INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5507","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PACRITINIB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PACRITINIB","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:12:21.462977","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:44:29.518634+00:00","fieldsConflicting":8,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ruxolitinib","drugSlug":"ruxolitinib","fdaApproval":"2011-11-16","patentExpiry":"Sep 4, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"fedratinib","drugSlug":"fedratinib","fdaApproval":"2019-08-16","patentExpiry":"Sep 24, 2039","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"NCE","date":"Feb 28, 2027"},{"code":"ODE-397","date":"Feb 28, 2029"}],"genericName":"pacritinib","indications":{"approved":[{"name":"Myelofibrosis","source":"DrugCentral","snomedId":52967002,"regulator":"FDA","eligibility":"Adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with platelet count below 50 10^9/L","usPrevalence":null,"globalPrevalence":240000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency[INST])"}],"offLabel":[],"pipeline":[]},"currentOwner":"Sobi","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"ruxolitinib","brandName":"ruxolitinib","genericName":"ruxolitinib","approvalYear":"2011","relationship":"same-class"},{"drugId":"fedratinib","brandName":"fedratinib","genericName":"fedratinib","approvalYear":"2019","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06303193","phase":"PHASE1,PHASE2","title":"Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-02","conditions":["Myelodysplastic Syndromes"],"enrollment":160,"completionDate":"2035-01-01"},{"nctId":"NCT05531786","phase":"PHASE1,PHASE2","title":"Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-06","conditions":["Graft vs Host Disease"],"enrollment":50,"completionDate":"2027-07-22"},{"nctId":"NCT07447817","phase":"PHASE2","title":"Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias","status":"NOT_YET_RECRUITING","sponsor":"John Mascarenhas","startDate":"2026-05-04","conditions":["Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":26,"completionDate":"2030-05-24"},{"nctId":"NCT07387354","phase":"PHASE1,PHASE2","title":"Pacritinib With Aza for Upfront Myelodysplastic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2026-05","conditions":["Myelodysplastic Syndromes","MDS","Myelodysplastic Syndrome, Unclassifiable","Hematologic Diseases","Bone Marrow Disease","Myeloproliferative Neoplasm"],"enrollment":25,"completionDate":"2027-01"},{"nctId":"NCT04282187","phase":"PHASE2","title":"Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-03-24","conditions":["Acute Myeloid Leukemia","Essential Thrombocythemia","Myelodysplastic Syndrome","Myelodysplastic/Myeloproliferative Neoplasm","Myeloproliferative Neoplasm","Myeloproliferative Neoplasm, Not Otherwise Specified","Polycythemia Vera","Primary Myelofibrosis","Secondary Myelofibrosis"],"enrollment":25,"completionDate":"2026-11-11"},{"nctId":"NCT06052618","phase":"PHASE2","title":"Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-17","conditions":["KSHV Inflammatory Cytokine Syndrome (KICS)","Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease"],"enrollment":75,"completionDate":"2034-01-01"},{"nctId":"NCT06782373","phase":"PHASE2","title":"A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2025-05-28","conditions":["VEXAS","VEXAS Syndrome"],"enrollment":78,"completionDate":"2028-05-22"},{"nctId":"NCT07033598","phase":"PHASE2","title":"Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Theradex","startDate":"2026-01-01","conditions":["Leukemia, Myelomonocytic, Chronic"],"enrollment":66,"completionDate":"2028-12"},{"nctId":"NCT07148947","phase":"PHASE2","title":"Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-03-02","conditions":["Accelerated Phase Myeloproliferative Neoplasm","Blast Phase Myeloproliferative Neoplasm"],"enrollment":27,"completionDate":"2028-12-31"},{"nctId":"NCT03165734","phase":"PHASE3","title":"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis","status":"RECRUITING","sponsor":"Swedish Orphan Biovitrum","startDate":"2017-06-26","conditions":["Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":399,"completionDate":"2027-07-30"},{"nctId":"NCT05980806","phase":"PHASE2","title":"A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2024-04-22","conditions":["Myelofibrosis","Moderate Thrombocytopenia","Mild Thrombocytopenia"],"enrollment":58,"completionDate":"2028-10"},{"nctId":"NCT07394153","phase":"PHASE2","title":"Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas","startDate":"2026-03","conditions":["Myelofibrosis，MF"],"enrollment":30,"completionDate":"2028-06"},{"nctId":"NCT02891603","phase":"PHASE1,PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":["Graft Vs Host Disease","GVHD"],"enrollment":40,"completionDate":"2022-04-18"},{"nctId":"NCT04858256","phase":"PHASE2","title":"Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2023-03-29","conditions":["T-Cell Neoplasm","Lymphoproliferative Disorders"],"enrollment":100,"completionDate":"2028-11"},{"nctId":"NCT06675123","phase":"PHASE1","title":"Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-02-01","conditions":["Recurrent Mantle Cell Lymphoma","Refractory Mantle Cell Lymphoma"],"enrollment":10,"completionDate":"2028-03-08"},{"nctId":"NCT06986174","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia","status":"RECRUITING","sponsor":"Shayna Sarosiek, MD","startDate":"2025-11-21","conditions":["Waldenström Macroglobulinemia","Lymphoplasmacytic Lymphoma","B-Cell Lymphoproliferative Disorder","Indolent Lymphoma"],"enrollment":30,"completionDate":"2032-10-01"},{"nctId":"NCT04635059","phase":"PHASE2","title":"Pacritinib for Biochemical Relapse After Definitive Treatment for Prostate Cancer","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2021-06-01","conditions":["Prostate Cancer"],"enrollment":6,"completionDate":"2024-10-27"},{"nctId":"NCT07226713","phase":"PHASE2","title":"Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":["Prostate Cancer"],"enrollment":32,"completionDate":"2031-03-01"},{"nctId":"NCT04520269","phase":"PHASE1,PHASE2","title":"A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-07-13","conditions":["Breast Cancer"],"enrollment":74,"completionDate":"2026-07"},{"nctId":"NCT06159491","phase":"PHASE1,PHASE2","title":"Pacritinib in CMML","status":"RECRUITING","sponsor":"Douglas Tremblay","startDate":"2024-09-18","conditions":["Chronic Myelomonocytic Leukemia"],"enrollment":26,"completionDate":"2027-07"},{"nctId":"NCT06538181","phase":"PHASE1","title":"Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-02-13","conditions":["E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome","VEXAS","Vexas Syndrome"],"enrollment":15,"completionDate":"2029-02-28"},{"nctId":"NCT06414681","phase":"EARLY_PHASE1","title":"Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy with the Approved JAK Inhibitors or in Which Therapy with the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined","status":"NOT_YET_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2025-03-28","conditions":["Myelofibrosis，MF"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT06516887","phase":"PHASE1,PHASE2","title":"Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-12-27","conditions":["Advanced Lung Adenocarcinoma"],"enrollment":44,"completionDate":"2027-09-01"},{"nctId":"NCT05552183","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability, and PK of Pacritinib","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2022-12-12","conditions":["Hepatic Impairment"],"enrollment":29,"completionDate":"2024-06-10"},{"nctId":"NCT05657613","phase":"PHASE1","title":"Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2023-01-03","conditions":["Drug Interactions"],"enrollment":60,"completionDate":"2023-06-08"},{"nctId":"NCT04404361","phase":"PHASE2","title":"PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2020-05-22","conditions":["COVID19","COVID-19","COVID"],"enrollment":200,"completionDate":"2021-09-21"},{"nctId":"NCT06218628","phase":"PHASE1","title":"Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2024-04-05","conditions":["Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Chronic Myelomonocytic Leukemia","Polycythemia Vera","Essential Thrombocytosis"],"enrollment":24,"completionDate":"2030-08-27"},{"nctId":"NCT02807116","phase":"PHASE1","title":"Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2015-01","conditions":["Healthy Subjects"],"enrollment":18,"completionDate":"2015-02"},{"nctId":"NCT02807207","phase":"PHASE1","title":"To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2014-10","conditions":["Healthy Subjects"],"enrollment":42,"completionDate":"2014-12"},{"nctId":"NCT02823171","phase":"PHASE1","title":"To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2015-08","conditions":["Healthy"],"enrollment":28,"completionDate":"2015-09"},{"nctId":"NCT02808455","phase":"PHASE1","title":"Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2015-01","conditions":["Healthy Subjects"],"enrollment":12,"completionDate":"2015-03"},{"nctId":"NCT03645824","phase":"PHASE2","title":"Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2018-06-04","conditions":["Myelofibrosis"],"enrollment":61,"completionDate":"2027-02"},{"nctId":"NCT04884191","phase":"PHASE2","title":"Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2017-07-31","conditions":["Primary Myelofibrosis","Post-Polycythemia Vera Myelofibrosis","Post- Essential Thrombocythemia Myelofibrosis"],"enrollment":165,"completionDate":"2019-09-04"},{"nctId":"NCT02055781","phase":"PHASE3","title":"Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2014-02","conditions":["Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":311,"completionDate":"2016-04"},{"nctId":"NCT01620216","phase":"PHASE2","title":"Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2012-05-11","conditions":["Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia","Refractory Acute Lymphoblastic Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":12,"completionDate":"2017-04-30"},{"nctId":"NCT02584777","phase":"PHASE2","title":"A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis","status":"WITHDRAWN","sponsor":"Baxalta now part of Shire","startDate":"2015-11-30","conditions":["Primary Myelofibrosis"],"enrollment":0,"completionDate":"2020-08-31"},{"nctId":"NCT03601819","phase":"PHASE1","title":"Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2019-05-15","conditions":["Lymphoma, T-Cell, Cutaneous","Lymphoma, T-Cell, Peripheral","Chronic Lymphocytic Leukemia","Lymphoproliferative Disorders","Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma","Mantle Cell Lymphoma"],"enrollment":4,"completionDate":"2020-07-17"},{"nctId":"NCT01773187","phase":"PHASE3","title":"Pacritinib Versus Best Available Therapy to Treat Myelofibrosis","status":"TERMINATED","sponsor":"CTI BioPharma","startDate":"2013-01","conditions":["Primary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis"],"enrollment":327,"completionDate":"2016-04"},{"nctId":"NCT02765724","phase":"PHASE1","title":"Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2015-01","conditions":["Myelofibrosis"],"enrollment":28,"completionDate":"2015-06"},{"nctId":"NCT02807051","phase":"PHASE1","title":"To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2014-09","conditions":["Drug Interaction Study"],"enrollment":20,"completionDate":"2014-10"},{"nctId":"NCT02323607","phase":"PHASE1","title":"Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations","status":"COMPLETED","sponsor":"Bhavana Bhatnagar","startDate":"2016-01-12","conditions":["Recurrent Adult Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia","Therapy-Related Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia"],"enrollment":13,"completionDate":"2018-07-12"},{"nctId":"NCT02410551","phase":"PHASE2","title":"Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-15","conditions":["Myeloproliferative Diseases"],"enrollment":4,"completionDate":"2017-01-20"},{"nctId":"NCT02807077","phase":"PHASE1","title":"PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2014-11","conditions":["Myelofibrosis"],"enrollment":40,"completionDate":"2015-07"},{"nctId":"NCT02469415","phase":"PHASE2","title":"Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-30","conditions":["Leukemia"],"enrollment":3,"completionDate":"2017-06-03"},{"nctId":"NCT02532010","phase":"PHASE2","title":"Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2015-06-15","conditions":["Acute Myeloid Leukemia (AML)"],"enrollment":13,"completionDate":"2017-10-24"},{"nctId":"NCT02342353","phase":"PHASE1","title":"Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2015-05-18","conditions":["Non-Small Cell Lung Cancer","Nonsmall Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung"],"enrollment":8,"completionDate":"2018-02-06"},{"nctId":"NCT02677948","phase":"PHASE1,PHASE2","title":"Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)","status":"WITHDRAWN","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2016-10","conditions":["Chronic Lymphocytic Leukemia","Lymphoma, Small Lymphocytic"],"enrollment":0,"completionDate":"2018-10"},{"nctId":"NCT02564536","phase":"PHASE1","title":"Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2017-06","conditions":["Chronic Myelomonocytic Leukemia","Juvenile Myelomonocytic Leukemia","Atypical Chronic Myeloid Leukemia","Myeloproliferative Neoplasm","Myelodysplastic Syndromes","Myelofibrosis"],"enrollment":0,"completionDate":"2020-06-30"},{"nctId":"NCT02277093","phase":"PHASE2","title":"Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2015-09-22","conditions":["Colorectal Cancer"],"enrollment":11,"completionDate":"2016-10-27"},{"nctId":"NCT02803762","phase":"PHASE1","title":"Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib","status":"COMPLETED","sponsor":"CTI BioPharma","startDate":"2014-07","conditions":["Healthy"],"enrollment":6,"completionDate":"2014-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Vonjo"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"357763","NDDF":"018971","UNII":"G22N65IL3O","VANDF":"4041252","INN_ID":"9385","RXNORM":"2595242","UMLSCUI":"C3467842","chemblId":"CHEMBL4778465","ChEMBL_ID":"CHEMBL2035187","KEGG_DRUG":"D04300","DRUGBANK_ID":"DB11697","PDB_CHEM_ID":"6T3","PUBCHEM_CID":"46216796","IUPHAR_LIGAND_ID":"7793","SECONDARY_CAS_RN":"1228923-42-9","MESH_SUPPLEMENTAL_RECORD_UI":"C561234"},"formularyStatus":[],"originalProduct":{"form":"CAPSULE","route":"ORAL","company":"CTI BioPharma Corp.","brandName":"Vonjo","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2022-","companyName":"Marinus Pharma Inc","relationship":"Original Developer"},{"period":"present","companyName":"Sobi","relationship":"Current Owner"}],"publicationCount":224,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01EJ03","allCodes":["L01EJ03"]},"biosimilarFilings":[],"originalDeveloper":"Marinus Pharma Inc","recentPublications":[{"date":"2026 Mar 18","pmid":"41851369","title":"Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial.","journal":"Bone marrow transplantation"},{"date":"2026 Feb 28","pmid":"41827733","title":"JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions.","journal":"Cancers"},{"date":"2026 Mar 12","pmid":"41812252","title":"Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?","journal":"Expert opinion on investigational drugs"},{"date":"2026 Feb 11","pmid":"41753113","title":"PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome.","journal":"Journal of clinical medicine"},{"date":"2026 Mar","pmid":"41504170","title":"Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy.","journal":"American journal of hematology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Sobi","companyId":"sobi","modality":"Small molecule","firstApprovalDate":"2022","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-02-28T00:00:00.000Z","mah":"SOBI","brand_name_local":null,"application_number":"NDA208712"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-03-18T00:00:00.000Z","mah":"MARINUS PHARMA INC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":14,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:44:29.518634+00:00","fieldsConflicting":8,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}